

Emmanuel Mignot, M.D., Ph.D.
Curriculum Vitae

Medical Licensure

California:	A067085
France:	LS/02032
American Board Sleep Disorders Medicine:	404

Professional Experience

United States:

2003-present	Director, Center for Narcolepsy, Stanford University
2009-present	Board Member, Center For Personalized Genomics and Medicine
2001-present	Professor of Psychiatry and Behavioral Sciences
2009-2019	Director, Stanford Center for Sleep Sciences and Medicine
2002-2009	Howard Hughes Medical Institute Investigator
1996-2001	Associate Professor of Psychiatry and Behavioral Sciences
1993-1996	Assistant Professor of Psychiatry and Behavioral Sciences
1988-1992	Visiting Assistant Professor of Psychiatry and Behavioral Sciences Basic Research Coordinator/Project Director of the Center for Narcolepsy, Sleep Research Center, Stanford University School of Medicine
1986-1988	Visiting Scholar, Sleep Disorders Clinic and Research Center, Stanford University School of Medicine

France:

1990-1992	Assistant Associé de Neurologie (without salary), Service de Physiopathologie des Maladies Nerveuse et Musculaires, Unité des troubles du sommeil, Centre Médical Gui de Chauliac, Montpellier
1988-1990	Attaché Assistant de Physiologie (without salary), Service d'exploration fonctionnelle, Faculté de Médecine Bicêtre, Hopital Antoine Beclère, Paris XI University School of Medicine
1984-1988	Assistant-Assistant de Pharmacologie, Service de pharmacologie, Médecine Necker Enfants Malades, Paris V University School of Medicine

Education

1990	Certification, American Board of Sleep Disorders and Clinical Polysomnography
1989	Psychiatry Doctorate, Paris V University, René Descartes School of Medicine
1986	Science Doctorate (option Biology), Paris VI University, Pierre and Marie Curie University, Sciences Faculty
1985	Diplome d' etude Approfondie (DEA) Neuropsychopharmacology, Paris VII University School of Medicine
1984	Medical Doctorate, Paris V University, René Descartes School of Medicine
1983-1987	Psychiatry Residency: Saint-Antoine Hospital (Pr. Alby, Paris), Sainte-Anne Hospital (Pr. Loo, Paris), Necker Enfants-Malades and Laennec Hospitals (Pr. Pelicier and Pr. Debray, Paris)
1982	Diplome d' etude Approfondie (DEA) Molecular Pharmacology and Biology, Paris VI University, Pierre and Marie Curie University, Sciences Faculty
1981	Master in Biochemistry, Paris VI University, Pierre and Marie Curie University, Sciences Faculty
1979-1984	Ecole Normale Supérieure (Ulm Science Section), Paris
1977-1984	Faculté de Médecine Necker, Paris V University School of Medicine

Awards

2015	Lifetime achievement award from the National Sleep Society
2013	Peter C. Farrell Prize in Sleep Medicine
2013	Elected member, National Academy of Sciences
2011	Elected member, Association of American Physicians
2009	Narcolepsy Network Scientific Research Award
2007	Pfizer lectureship in sleep medicine-U Michigan Award
2006	Sleep Research Society – Outstanding Scientific Achievement Award
2006	Elected member, Institute of Medicine, National Academy of Sciences
2004	College of Physicians and Surgeons of Columbia University – W. Alden Spencer Award
	American Neurological Association's Foster Elting Bennett Memorial Lecture Award
2002	American Academy of Neurology: Frontiers in Clinical Neuroscience: Beyond the Decade of the Brain Plenary Session Lecturer Award
2002	Howard Hughes Medical Institute Investigator Award
2002	McKnight Neuroscience of Brain Disorders Award
2001	Novo Nordisk Foundation-Jacobaeus Award
2001	Sleep Research Society – Outstanding Basic Research Contribution to Sleep Medicine award
2000	American College Neuropsychopharmacology (ACNP) – Excellence in Research in Neuropsychopharmacology Award
2000	American Academy of Sleep Medicine – William C Dement Academic Achievement Award and Keynote Address2000 Collegium

	Internationale Neuro-Psychopharmacologicum (CINP) Award Research in the Treatment of Sleep Disorders
1999	National Institute of Neurological Disease and Stroke (NINDS) Javits Award
1999	Narcolepsy Network Professional Service Award
1997	National Sleep Foundation Award for Narcolepsy Research
1992	Drs. C. and F. Demuth 11th Award for Young Investigators in Neurosciences
1984	Silver Medal, Doctorate in Medicine (thesis)
1984	Ecole Normale Superieure (Ulm Science Section), Paris

Professional Associations and Services

American Academy of Sleep Medicine (AASM): Member 1994-2004; Chairman, Research, 1995-1998; Gamma Hydroxybutyrate Task Force, 1998; Animal rights task force 1998-1999; Academic Advisory Board /Pfizer Scholars Grants in Sleep Medicine, 2005-2006.

American Association for the Advancement of Science (AAAS): Member, 1990-present
American College of Neuropsychopharmacology, Member, 2000-present

American Thoracic Association (ATS): Member of committee on inheritance & ventilatory control, 1999

Association of Professional Sleep Societies (APSS): Program committee member, 2005-2007.

Association de Psychiatrie Biologique: Member, 1985-1988

Association des Pharmacologistes: Member 1985-1989

European Sleep Research Society (ESRS): Member 1991-present

Food and Drug Administration (FDA): Peripheral and Central Nervous System Drugs Advisory Committee: Member, 2003-present

International Classification of Sleep Disorders (ICSD): Revision, 2nd Edition Task Force: Chair, Hypersomnia Task Force, 2002-2005.

Journal Biological Psychiatry: Editorial board member, 2001-2004

Journal Neuropsychopharmacology: Editorial Board Member, 2003-present

Journal Public Library of Sciences-Biology (PLoS-Biology): Editorial Board Member, 2005-present

Journal Sleep: Editorial Board member, 1995-present; Chairman of the search committee for editor in chief, 1996 and 2001; Editor in Chief 1996-present.

Journal Sleep Medicine: Editorial board member, 1999-present

Journal Sleep Research On-line: Editorial board member 1997-present, Section Editor, Molecular Biology, 1997-2001

Kleine-Levin Syndrome Foundation: Member, Medical Advisory Board, 2005-present

National Academy of Sciences, Institute of Medicine (NAS/IOM): Board on Neuroscience and Behavioral Health: Board Member, 2002-2004; Study Task Force on Sleep Research and Medicine: Member, 2005-2006

National Institutes of Health (NIH/NHLBI): Candidate-gene Associated Resource (CARE) Steering Committee, member, 2006.

National Institutes of Health (NIH): NIH Roadmap for Medical Research, consultant, 2006.

National Institute of Mental Health (NIH/NIMH): National Advisory Mental Health Council, Mood Disorders Workgroup, 2002-2003; Board of Scientific Counselors (BSC), Standing Board member, 2004-present

National Center on Sleep Disorders Research (NIH/NHLBI): Advisory Board Member, 1998-2002; Chairman of the Board, 2001-2002; Sleep Disorders Research Plan Revision Task Force (NIH/NHLBI): Member, 2002-2004
National Human Genome Research Institute (NIH/NHGRI) Medical Sequencing RC2 panel Review, 2009.
National Sleep Foundation: Chairman, Narcolepsy Council, 1994-present; Board Member, 2000-2005
Ordre des Médecins (French MD licensing board): Member, 1984-present
PLoS Biology. Editorial board member, 2005-present
Restless Leg Syndrome Foundation: Board of Scientific Advisory Board: Member 2005-present
Sleep Medicine Network, Chair of the executive committee 2008-present.
Sleep Research Society: Member 1990-present; Member at large, 1992-1994; Board Member 2005-present, Animal Rights CARE Committee, 2000-2002; President Elect 2002; President 2003; Past president 2004; Academic Sleep Center Task Force, 2007-present; Sleep and genetic task force, 2008-present.
Thirteen International Histocompatibility Workshop and Conference (13thIHW): Narcolepsy Section, Disease Component, Chairman, 1997-2003

Reviewer

Peer Reviewed Journals:

American Journal of Human Genetics; American Journal of Physiology; American Journal of Respiratory and Critical Care; Annals of Neurology; Biochemistry and Behavior; Biological Psychiatry; Brain Research; Cell; Chronobiology International; Current Biology; Endocrinology and Metabolism; Experimental Opinions in Investigational Drugs; European Journal of Immunogenetics; European Journal of neurosciences; Immunogenetics; Journal of American Medical Association; Journal of Biological Rhythms; Journal of Experimental Medicine and Therapeutics; Journal of Neurosciences; Journal of Psychosomatic Research; Journal of Sleep Research; Life Sciences; Medicine; Molecular Psychiatry; Nature; Nature Neurosciences; Neurology; Neuron; Neuropharmacology; Neurosciences; Neurophysiology; New England J of Medicine; PLoS Biology; PLoS Medicine; Peptides; Pharmacology; Physiology and Behavior; Proceedings of the National Academy of Sciences (USA); Psychological Medicine; Psychopharmacology; Research Communications in Biological Psychology and Psychiatry; Regulatory Peptides; Science; Science Translational Medicine: Sleep; Sleep Medicine; Sleep Medicine Review; Sleep Research OnLine; Lancet; Tissue Antigens

Research Institutes:

Center for Scientific Review: "Clinical Neuroscience and Biological Psychopathology Study Section", standing member, 1995-1997
National Institute of Mental Health (NIMH), Board of Scientific Counselors (BSC): Intramural NIHM Reviewer, Ad hoc reviewer 2001, Standing Member, 2004-present, Chair 2007-2009.

Ad hoc reviewer for other Study Sections and NIH Institutes: NINDS, NIMH, NHLBI, NIA, NHGR, Medical Research Council (MRC, Canada), Telethon (Italy), DRG (Germany), Air Force Grant reviewer

Foundations:

*American Academy of Sleep Medicine (AASM): Academic Advisory Board Reviewer
Grants in Sleep Medicine: 2001-present.*

National Sleep Foundation: Pickwick fellowship Award Reviewer, 1998-present

Restless Legs Syndrome Foundation: Board of Scientific Advisory and Reviewer, 2005-present

Klarman Family Foundation Grants Program: Reviewer, 2007-2012

Teaching and Congress Organization

1996-1998	PGYIII Psychiatry residents, Neuroscience: Course Director
1999- present	Sleep disorders and physiology of sleep and circadian rhythms, course director
1994-1998	Stanford Undergraduates, Sleep and Dreams
1991-present	Sleep Medicine Residents
1998-present	Stanford Sleep Medicine Course, Palo Alto School of Sleep Medicine
2001-present	American Academy of Sleep Medicine refresher course
2005-2007	Annual Meeting of the Association of Professional Sleep Societies (APSS): Program committee members
2005-present	Medical Student Education Grants Review Committee and Mentorship, Neuroscience Concentration
2007	Keystone meeting: Genetics and Biochemistry of Sleep, March 7 - 12, 2008 at Granlibakken Resort, Tahoe City, California, coorganization with A. Seghal, J. Dunlap.

Publications

Current H index: 100

Over 400 abstracts and presentations at conferences not included.

Peer Reviewed Manuscripts Containing Original Data:

1. **Mignot E**, Laude D, Elghozi JL, Le Quan-Bui KH, Meyer P (1982). Central administration of yohimbine increases free 3-methoxy-4-hydroxyphenylethylenglycol in the CSF of the rat. *Eur. J. Pharmacol.*, 83: 135-138.
2. **Mignot E**, Laude D, Elghozi JL, Le Quan-Bui KH, Meyer P (1983). Effets de la yohimbine et de l'halopéridol sur les métabolites des monoamines du liquide céphalorachidien du rat (in French). *Acta Pharmacol. Biol. Clin.*, 2: 144-147.

3. Elghozi JL, Le Quan-Bui KH, **Mignot E**, Laude D, Devynck MA (1983). Recueil continu de liquide céphalorachidien de rat: Application à la détermination des métabolites des monoamines (in French). *Acta Pharmacol. Biol. Clin.*, 2: 180-183.
4. Elghozi JL, Laude D, **Mignot E**, Meyer P (1983). Détermination de l'alpha méthyl DOPA, de l'acide dihydrophénylacétique et de l'acide 5-hydroxy-indolacétique dans le liquide céphalorachidien du rat. Etude cinétique (in French). *Archives des Maladies du Coeur et des Vaisseaux. N° special*, pp. 13-17.
5. Elghozi JL, **Mignot E**, Le Quan-Bui KH (1983). Probenecid-sensitive pathway of elimination of dopamine and serotonin metabolites in CSF of the rat. *J. Neural Trans.*, 57: 85-94.
6. Elghozi JL, Laude D, **Mignot E**, Meyer P (1983). Determination of alpha-methyl DOPA, dihydrophenylacetic acid and 5-hydroxy-indol acetic acid in the cerebrospinal fluid of the rat: kinetic study (in French). *Eur. Heart J.*, 4 (suppl G): 31-34.
7. **Mignot E**, Laude D, Elghozi JL (1984). Kinetics of drug induced changes in dopamine and serotonin metabolite levels on CSF of the rat. *J. Neurochem.*, 42: 819-825.
8. Elghozi JL, Danguir J, **Mignot E**, Laude D (1984). Brain amine metabolism is reflected in cerebral ventricular CSF in body fluid homeostasis. *J. Physiol. (Paris)*, 79: 531-535.
9. Elghozi JL, Laude D, Duprat P, **Mignot E** (1984). Pizotifen increases 5-HIAA urinary excretion in male healthy volunteers. *Eur. J. Clin. Pharmacol.*, 27: 191-196.
10. Chaouloff F, Laude D, **Mignot E**, Kamoun P, Elghozi JL (1985). Tryptophan and serotonin turnover rate in the brain of genetically hyperammonemic mice. *J. Neurochem.*, 7: 143-147.
11. Duval C, **Mignot E** (1985). Effects of rat ovariectomy on CSF monoamine metabolite levels and elimination. *J. Neurochem.*, 44: 1312-1314.
12. **Mignot E**, Serrano A, Laude D, Elghozi JL, Derek J, Scatton B (1985). Measurement of 5-HIAA levels in ventricular CSF (by LCEC) and striatum (by *in vivo* voltammetry) during pharmacological modifications of serotonin metabolism in the rat. *J. Neural. Transm.*, 62: 117-124.
13. **Mignot E**, Laude D (1985). The study of dopamine turnover by monitoring the decline of dopamine metabolites in rat CSF after alpha-methyl-p-tyrosine. *J. Neurochem.*, 45: 1527-1533.
14. **Mignot E**, Guilleminault C, Bowersox S, Rappaport A, Dement WC (1988). Effect of alpha 1 adrenoceptors blockage with prazosin in canine narcolepsy. *Brain Res.*, 444: 184-188.
15. **Mignot E**, Garcia A, Laude D, Elghozi JL, Guicheney P, Gilbert JC, Alby JM, Plaisant O, Debray Q, Pelicier, Y, Meyer P (1988). Value of plasma HVA level in human: Influence of renal function, food intake and psychiatric state. *Biogenic Amines*, 5(2): 169-176.
16. **Mignot E**, Guilleminault C, Bowersox S, Rappaport A, Dement WC (1988). A role of central alpha 1 adrenoceptors in canine narcolepsy. *J. Clin. Invest.*, 82: 885-894.
17. Guilleminault C, **Mignot E**, Aldrich M, Quera-Salva MA, Tiberge M, Partinen M (1988). Prazosin contraindicated in patients with narcolepsy. *Lancet*, 609: 511-512.

18. **Mignot E**, Bowersox SS, Maddaluno J, Dement WC, Ciaranello RD (1989). Evidence for multiple [3H]-prazosin binding sites in canine brain membranes. *Brain Res.*, 486: 56-66.
19. Nishino S, **Mignot E**, Fruhstorfer B, Dement WC, Hayaishi O (1989). Prostaglandin E₂ and its methylester reduce cataplexy in canine narcolepsy. *Proc. Natl. Acad. Sci. USA (USA)*, 86: 2483-2487.
20. **Mignot E**, Guilleminault C, Bowersox S, Fruhstorfer B, Nishino S, Maddaluno J, Ciaranello R, Dement W (1989). Central alpha-1 adrenoceptor subtypes in narcolepsy-cataplexy: a disorder of REM sleep. *Brain Res.*, 490: 186-191.
21. Garcia A, Galinowski A, Guicheney P, **Mignot E**, Loo H, Meyer P (1989). Free and conjugated plasma homovanillic acid in schizophrenic patients. *Biol. Psychiatry*, 26: 87-96.
22. Fruhstorfer B, **Mignot E**, Bowersox S, Nishino S, Dement W, Guilleminault C (1989). Canine narcolepsy is associated with an elevated number of alpha-2 receptors in the locus coeruleus. *Brain Res.*, 500: 209-214.
23. Guilleminault C, **Mignot E**, Grumet C (1989). Familial patterns of narcolepsy. *Lancet*, 333: 1376-1379.
24. Nishino S, Haak L, Sheperd H, Guilleminault C, Sakai T, Dement WC, **Mignot E** (1990). Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of REM sleep. *J. Pharmacol. Exp. Ther.*, 253(3): 1145-1152.
25. Nishino S, **Mignot E**, Kilduff T, Sakai T, Toshiaki S, Hayaishi O, Dement WC (1990). Prostaglandin E₂ levels in cerebrospinal fluid of normal and narcoleptic dogs. *Biol. Psychiatry*, 28: 904-910.
26. Hawkins M, O'Connor S, Radulavacki M, Bowersox S, **Mignot E**, Dement W C (1991). Radioligand binding to adenosine receptors and adenosine uptake sites in different brain regions of normal and narcoleptic dogs. *Pharmacol. Biochem. Behav.*, 38(1): 1-6.
27. Mignot E, Wang C, Rattazzi C, Gaiser C, Lovett M, Guilleminault C, Dement WC, Grumet FC (1991). Genetic linkage of autosomal recessive narcolepsy with an immunoglobulin μ chain switch-like segment. *Proc. Natl. Acad. Sci.*, 88: 3475-3478.
28. Siegel JM, Nienhuis R, Fahringer H, Paul R, Shiromani P, Dement WC, **Mignot E**, Chiu C (1991). Neuronal activity in narcolepsy: Identification of cataplexy related cells in the medial medulla. *Science*, 252: 1315-1318.
29. Valtier D, Nishino S, **Mignot E**, Guilleminault C, Dement W, Mignot E (1991). Platelet alpha-2 adrenoceptors in human and canine narcolepsy. *Biol. Psychiatry*, 29: 376-382.
30. Nishino S, Arragoni J, Valtier D, Miller J, Guilleminault, C, Dement WC, **Mignot E** (1991). Dopamine D₂ mechanisms in canine narcolepsy. *J. Neurosci.*, 11: 2666-2671.
31. Renaud A, Nishino S, Dement WC, Guilleminault C, **Mignot E** (1991). Effects of SDZ NVI-085, a putative subtype selective alpha-1 agonist on canine cataplexy, a disorder of REM sleep. *Eur. J. Pharmacol.*, 205: 11-16.
32. Haak L, **Mignot E**, Kilduff T, Dement WC, Heller C (1991). Regional changes in central monoamine and metabolite levels during the hibernation cycle in the golden mantled ground squirrel *citellus lateralis*. *Brain Res.*, 563: 215-220.

33. Matsuki K, Grumet FC, Lin X, Gelb M, Guilleminault C, Dement WC, **Mignot E** (1992). DQ rather than DR gene marks susceptibility to narcolepsy. *Lancet*, 339: 1052.
34. Siegel JM, Nienhuis R, Fahringer HM, Chiu C, Dement WC, **Mignot E**, Lufkin R (1992). Activity of medial mesopontine units during cataplexy and sleep waking states in the narcoleptic dog. *J. Neurosci.*, 12: 1640-1646.
35. Nishino S, Arrigoni J, Sharp L, Shelton J, Dement WC, **Mignot E** (1992). Serum prolactin response to a D2 antagonist in narcoleptic and control canines. *Sleep*, 15(5): 474-475.
36. **Mignot E**, Lin X, Kalil J, George C, Singh S, Billiard M, Montplaisir J, Arrigoni J, Guilleminault C, Dement WC, Grumet FC (1992). DQB1-0602 (DQw1) is not present in most non-DR2 caucasian narcoleptics. *Sleep*, 15(5): 415-422.
37. Valtier D, Dement WC, **Mignot E** (1992). Monoaminergic uptake in synaptosomes of normal and narcoleptic canines prepared from frozen brain tissue samples. *Brain Res.*, 588: 115-119.
38. **Mignot E**, Nishino S, Hunt-Sharp L, Arrigoni J, Siegel JM, Reid MS, Edgar DM, Ciaranello RD, Dement WC (1993). Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: Induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. *J. Neurosci.*, 13(3): 1057-1064.
39. Nishino S, Frushtorfer B, Arrigoni J, Guilleminault C, Dement WC, **Mignot E** (1993). Further characterization of an alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. *J. Pharmacol. Exp. Ther.*, 264(3): 1079-1084.
40. **Mignot E**, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC (1993). Canine cataplexy is preferentially controlled by adrenergic mechanisms: Evidence using monoamine selective uptake inhibitors and release enhancers. *J. Psychopharmacol.*, 113(1): 76-82.
41. Nishino S, Arrigoni J, Shelton J, Dement WC, **Mignot E** (1993). Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. *Sleep*, 16(8): 706-712.
42. Le Quan-Sang KH, **Mignot E**, Gilbert JC, Huguet R, Aquino JP, Regnier O, Devynck MA (1993). Platelet cytosolic free calcium concentration is increased in aging and Alzheimer's disease. *Biol. Psychiatry*, 33: 391-393.
43. **Mignot E**, Hesla P, Pask S, Lin X, Kayed K, Arrigoni J, Dement WC, Grumet FC (1993). A novel HLA DR17, DQ1 (DQA1-0102/DQB1-0602 positive) predisposing to narcolepsy in Caucasians. *Sleep*, 16(9): 764-765.
44. Reid MS, Tafti M, Geary JN, Nishino S, Siegel JM, Dement WC, **Mignot E** (1994). Cholinergic mechanisms in canine narcolepsy: I. modulation of cataplexy via local drug administration into the pontine reticular formation. *J. Neurosci.*, 59(3): 511-522.
45. Reid MS, Tafti M, Siegel JM, Dement WC, **Mignot E** (1994). Cholinergic mechanisms in canine narcolepsy: II. Acetylcholine release in the pontine reticular formation is enhanced during cataplexy. *J. Neurosci.*, 59(3): 523-530.

46. Gelb M, Guilleminault C, Lin S, Moon S, Dement WC, **Mignot E** (1994). Stability of cataplexy over several months--information for the design of therapeutic trials. *Sleep*, 17(3): 265-273.
47. Grumet FC, **Mignot E** (1994). A non-DR2 narcoleptic patient with a unique DRB1-08del, DQB1-0602 haplotype having a new DRB1 allele with a codon deletion. *Hum. Immunol.*, 39: 302.
48. Reid MS, Tafti M, Nishino S, Siegel JM, Dement WC, **Mignot E** (1994). Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. *Sleep*, 17(5): 424-435.
49. **Mignot E**, Nishino S, Guilleminault C, Dement WC (1994). Modafinil binds the dopamine uptake carrier site with low affinity. *Sleep*, 17(5): 436-437.
50. Guilleminault C, **Mignot E**, Partinen M (1994). Controversies in the diagnosis of narcolepsy. *Sleep*, 17(8): S1-S6.
51. **Mignot E**, Lin X, Arrighoni J, Macaubas C, Olive F, Hallmeyer J, Underhill P, Guilleminault C, Dement WC, Grumet FC (1994). DQB1-0602 and DQA1-0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans. *Sleep*, 17(8): S60-S67.
52. **Mignot E**, Bell RA, Rattazzi C, Lovett M, Dement WC, Grumet FC (1994). An immunoglobulin switch like sequence is linked with canine narcolepsy. *Sleep*, 17(8): S68-S76.
53. Behar E, Lin X, Grumet FC, **Mignot E** (1995). A novel HLA DRB1*1202 allele (DRB1*12022) found in association with DQA1*0102 and DQB1*0602 in two black narcoleptic subjects. *Immunogenetics*, 41(1): 52.
54. Macaubas C, Hallmeyer J, Kalil J, Grumet FC, **Mignot E** (1995). Extensive polymorphism of a (CA)_n microsatellite located in the HLA-DQA1/DQB1 class II region. *Hum. Immunol.*, 42(3): 209-220.
55. Nishino S, Shelton J, Renaud A, Dement WC, **Mignot E** (1995). Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy. *J. Pharmacol. Exp. Ther.*, 272(3): 1170-1175.
56. Nishino S, Tafti M, Reid M, Shelton J, Siegel JM, Dement WC, **Mignot E** (1995). Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: Implication for the pathophysiology of canine narcolepsy. *J. Neurosci.*, 15(7): 4806-4814.
57. Nitz D, Andersen A, Fahringer H, Nienhuis R, **Mignot E**, Siegel J (1995). Altered distribution of cholinergic cells in the narcoleptic dog. *NeuroReport*, 6(11): 1521-1524.
58. **Mignot E**, Kimura A, Abbal M, Thorsby E, Lin X, Voros A, Macaubas C, Bouissou F, Sollid LM, Cambon-Thomsen A, Yasunga S, Grumet FC (1995). DQCAR microsatellite polymorphisms in three selected HLA Class II-associated diseases. *Tissue Antigens*, 46: 299-304.
59. Kanbayashi T, Nishino S, Tafti M, Hishikawa Y, Dement WC, **Mignot E** (1996). Thalidomide, immune modulation and narcolepsy. *Sleep*, 19(2): 116.
60. Shelton J, Nishino S, Vaught J, Dement WC, **Mignot E** (1996). Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. *Sleep*, 18(10): 817-826.
61. Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel J, **Mignot E** (1996). Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. *Brain Res.*, 733(1): 83-100.

62. Dutra AS, **Mignot E**, Puck JM (1996). Gene localization and syntenic mapping by FISH in the dog. *Cytogenet., Cell Genet.*, 74(1-2): 113-117.
63. Singh SM, George CF, Ott RN, Rattazzi C, Guilleminault C, Dement WC, **Mignot E** (1996). IgH (μ -switch & gamma-1) region restriction fragment length polymorphism in human narcolepsy. *J. of Clin. Immunol.*, 16(4): 208-215.
64. Jin L, Macaubas C, Hallmayer J, Kimura, A, **Mignot E** (1996). Mutation rate varies among alleles at a microsatellite locus: Phylogenetic evidence. *Proc. Natl. Acad. Sci. USA*, 93(26): 15285-15288.
65. Tafti M, Nishino S, Aldrich MS, Liao W, Dement WC, **Mignot E** (1996). Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in a canine model. *J. Neurosci.*, 16(15): 4588-4595.
66. Kanbayashi T, Nishino S, Tafti M, Hishidawa Y, Dement WC, **Mignot E** (1996). Thalidomide, a hypnotic with immune modulating properties in canine narcolepsy. *Neuroreport*, 7(12): 1881-1886.
67. Rogers A, Meehan J, Guilleminault C, Grumet FC, **Mignot E** (1997). HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. *Neurology*, 48(6): 1550-1556.
68. **Mignot E**, Kimura A, Lattermann A, Lin X, Yasunaga S, Mueller-Eckhardt G, Rattazzi C, Lin L, Guilleminault C, Grumet FC, Mayer G, Dement WC, Underhill P. (1997). Extensive HLA Class II studies in 58 non DRB1*15 (DR2) narcoleptic patients with cataplexy. *Tissue Antigens*, 49: 329-341.
69. Nishino S, Arrigoni J, Shelton J, Kanbayashi T, Dement WC, **Mignot E** (1997). Effects of tyrotropine releasing hormone (TRH) and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. *J. Neurosci.*, 17(16): 6401-6408.
70. Nishino S, Tafti M, Sampathkumaran R, Dement WC, **Mignot E** (1997). Circadian distribution of rest-activity in narcoleptic and control dogs: Assessment with ambulatory activity monitoring. *J. Sleep Res.*, 6: 120-127.
71. Tafti M, Nishino S, Liao W, Dement WC, **Mignot E** (1997). Mesopontine organization of cholinergic and catecholaminergic cell groups in normal and narcoleptic dogs. *J. Comp. Neurol.*, 379: 185-197.
72. Lin L, Jin L, Kimura A, Carrington M, **Mignot E** (1997). DQ microsatellite association studies in three ethnic groups. *Tissue Antigens*, 50: 507-520.
73. Nevsímalová S, **Mignot E**, Sonka K, Arrigoni JL (1997). Familial aspects of narcolepsy-cataplexy in the Czech Republic. *Sleep*, 20(11): 1021-1026.
74. Ellis M, Hetsimer AH, Ruddy DA, Hansen SL, Kronmal GS, McClelland E, Quintana L, Drayna DT, Aldrich MS, **Mignot E** (1997). HLA Class II haplotype and sequence analysis support a role for DQ in narcolepsy. *Immunogenetics*, 46: 410-417.
75. Macaubas C, Jin L, Hallmayer J, Kimura A, **Mignot E** (1997). The complex mutation pattern of a microsatellite. *Genome Res.*, 7: 635-641.
76. **Mignot E**, Hayduk R, Grumet FC, Black J, Guilleminault C (1997). HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. *Sleep*, 20(11): 1012-1020.
77. Honda K, Riehl J, Inoué S, **Mignot E**, Nishino S (1997). Central administration of vitamin B12 aggravates cataplexy in canine narcolepsy. *Neuroreport*, 8: 3861-3865.

78. Reid M, Nishino S, Tafti M, Siegel JM, Dement WC, **Mignot E** (1997). Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. *Exp. Neurol.*, 151(1): 89-104.
79. Pelin Z, Guilleminault C, Risch N, Grumet FC, US Modafinil in Narcolepsy Multicenter Study Group, **Mignot E** (1997). HLA DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. *Tissue Antigens*, 51: 96-100.
80. Nishino S, **Mignot E**, Benson KL, Zarcone ZP (1998). Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and control: relationship to sleep architecture. *Psychiatry Res.*, 78(3): 141-150.
81. Cederberg R, Nishino S, Dement WC, **Mignot E** (1998). Breeding history of the Stanford colony of narcoleptic dogs. *Vet. Rec.*, 142: 31-36.
82. Martin MP, Harding A, Chadwick R, Kronick M, Cullen M, Lin L, **Mignot E**, Carrington M (1998). Characterization of 12 microsatellite loci of the human MHC in a panel of reference cell lines. *Immunogenetics*, 47(2): 131-138.
83. Nishino S, Mao J, Sampathkuraran R, Shelton J, **Mignot E** (1998). Increased dopaminergic transmission mediates alerting effects of CNS stimulants. *Sleep Research Online*, 1(1): 49-61.
84. Lin L, Jin L, Lin X, Voros A, Undershill P, **Mignot E** (1998). Microsatellite single nucleotide polymorphisms in the HLA-DQ region. *Tissue Antigens*, 52: 9-18.
85. **Mignot E**, Young T, Lin L, Finn L, Palta M (1998). Reduction of REM sleep latency associated with HLA-DQB1*0602 in normal adults. *Lancet*, 351: 727.
86. Riehl J, Nishino S, Cederberg R, Dement WC, **Mignot E** (1998). Development of cataplexy in genetically narcoleptic Dobermans. *Exp. Neurol.*, 152: 292-302.
87. Katzenberg D, Young T, Finn L, Lin L, King DP, Takahashi JS, **Mignot E** (1998). A *CLOCK* polymorphism associated with human diurnal preference. *Sleep*, 21(6): 568-575.
88. Nishino S, Honda K, Riehl J, Okura M, **Mignot E** (1998). Neuronal activity in the cholinceptive basal forebrain of freely-moving narcoleptic Dobermans. *Neuroreport*, 9: 3653-3661.
89. Anic-Labat S, Guilleminault C, Kraemer HC, Meehan J, Arrigoni J, **Mignot E** (1999). Validation of a cataplexy questionnaire in 983 sleep disorder patients. *Sleep*, 22(1): 77-87.
90. **Mignot E**, Young T, Lin L, Finn L (1999). Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. *Sleep*, 22(3): 347-352.
91. Siegel JM, Nienhuis R, Gulyani S, Ouyang S, Wu MF, **Mignot E**, Switzer RC, McMurry G, Cornford M (1999). Neuronal degeneration in canine narcolepsy. *J. Neurosci.*, 19: 248-57.
92. Li R, **Mignot E**, Faraco J, Kodatani H, Cantanese JJ, Zhao BH, Lin X, Hinton L, Ostrander EA, Patterson DF, de Jong P (1999). Construction and characterization of an eight fold redundant dog genomic bacterial artificial chromosome library. *Genomics*, 58: 9-17.
93. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong P, Nishino S, **Mignot E** (1999). The sleep disorder canine narcolepsy is caused by a mutation in the *hypocretin* (orexin) receptor 2 gene. *Cell*, 98(3): 365-376.

94. Honda K, Riehl J, **Mignot E**, Nishino S (1999). Dopamine D₃ agonists into the substantia nigra aggravate cataplexy but do not modify sleep. *Neuroreport*, 17(10): 3717-3724.
95. Katzenberg D, Young T, Lin L, Finn L, **Mignot E** (1999). A human period gene (HPER1) polymorphism is not associated with diurnal preference in normal adults. *Psychiatr. Genet.*, 9(2): 107-109.
96. Riehl J, Okura M, **Mignot E**, Nishino S (2000). Inheritance of Von Willerbrand's disease in a colony of Doberman pinschers. *Am. J. Vet. Res.*, 61(2): 115-20.
97. Riehl J, Honda K, Kwan M, Hong J, **Mignot E**, Nishino S (2000). Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. *Neuropsychopharmacology*, 23(1): 34-45.
98. Hong SC, Hayduk R, Lim J, **Mignot E** (2000). Clinical and polysomnographic features in DQB1*0602 positive and negative narcolepsy patients: results from the modafinil clinical trial. *Sleep Med.*, 1(1): 33-39.
99. Pedrazzoli M, Lin L, Finn L, Young T, Katzenberg D, **Mignot E** (2000). A polymorphism in the human timeless gene is not associated with diurnal preferences in normal adults. *Sleep Research Online*, 3(2): 73-76.
100. Nishino S, Ripley B, Overeem S, Lammers GJ, **Mignot E** (2000). Hypocretin (orexin) transmission is defective in human narcolepsy. *Lancet*, 355: 39-40.
101. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Liu C, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, **Mignot E** (2000). A mutation in early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nat. Med.*, 6(9): 991-997.
102. Nishino S, Riehl J, Hong J, Kwan M, Reid M, **Mignot E** (2000). Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. *Neurosc. Res.*, 38(4): 437-446.
103. Okura M, Riehl J, **Mignot E**, Nishino S (2000). Sulpiride, a D₂/D₃ blocker, reduces cataplexy but not REM sleep in canine narcolepsy. *Neuropsychopharmacology*, 23 (5): 528-538.
104. Kanbayashi T, Honda K, Kodama T, **Mignot E**, and Nishino S (2000). Implication of dopaminergic mechanisms in the wake promoting effects of amphetamine: A study of D- and L- derivatives in canine narcolepsy. *Neuroscience*, 99(4): 651-659.
105. Melberg A, Ripley B, Lin L, Hetta J, **Mignot E**, Nishino S (2001). Hypocretin deficiency in familial symptomatic narcolepsy. *Ann. Neurol.*, 49: 136-137.
106. Li R, Faraco JH, Lin L, Lin X, Hinton L, Rogers W, Lowe JK, Ostrander EA, **Mignot E** (2001). Physical and radiation hybrid mapping of canine chromosome 13, in a region corresponding to human chromosome 6p12-6q12. *Genomics*, 73: 299-315.
107. **Mignot E**, Lin L, Rogers W, Honda Y, Qiu X, Lin X, Okun M, Hohjoh H, Miki T, Hsu SH, Leffell MS, Grumet CF, Fernandez-Vina M, Honda M, Risch N. (2001). Complex HLA-DR and DQ interactions confer risk for narcolepsy-cataplexy in three ethnic groups. *Am. J. Hum. Genet.*, 68: 686-699.

108. Kadotani H, Kadotani T, Young T, Peppard PE, Finn L, Colrain IM, Murphy GM, **Mignot E** (2001). Apolipoprotein E 4 predisposes to sleep disordered breathing in the general adult population. *JAMA*, 285(22): 2888-2890.
109. Hungs M, Fan J, Lin L, Lin X, Grigoriadis D, Maki RA, **Mignot E** (2001). Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. *Genome Res.*, 11(4): 531-539.
110. Fujiki N, Yoshida Y, Ripley B, Honda K, **Mignot E**, Nishino S (2001). Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. *Neuroreport*, 12(5): 993-997.
111. Ripley B, Okura, M, Fujiki N, **Mignot E**, Nishino S (2001). Hypocretin levels in sporadic and familial cases of canine narcolepsy. *Neurobiol. Dis.*, 8: 525-534.
112. Wisor JP, Nishino S, Sora I, Uhl GH, **Mignot E**, Edgar DM (2001). Sleep regulation and response to stimulants are impaired in DAT knockout mice. *J. Neurosci.*, 21(5): 1787-1794.
113. Scammell TE, Nishino S, **Mignot E**, Saper CB (2001). Narcolepsy and low CSF orexin (hypocretin) concentration following a diencephalic stroke. *Neurology*, 56: 1751-1753.
114. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, Okun M, Rogers W, Brooks S, **Mignot E** (2001). Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. *Ann. Neurol.*, 50: 381-388.
115. Hungs M, Lin L, Okun M, **Mignot E** (2001). Polymorphisms in the vicinity of the Hypocretin/orexin are not associated with human narcolepsy. *Neurology*, 57: 1895-1895.
116. Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H, **Mignot E**, Nishino S (2001). Fluctuation of extracellular hypocretin-1 (orexin-A) levels in the rat in relation to the light/dark cycle and sleep/wake activities. *European J. Neurosci.*, 14: 1075-1081.
117. Nishino S, Fujiki N, Ripley B, Sakurai E, Kato M, Watanabe T, **Mignot E**, Yanai K (2001). Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. *Neurosci. Lett.*, 313: 125-128.
118. Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, Di Monte D, Dohi K, Melberg A, Lammers GJ, Nishida Y, Roelandse FWC, Hungs M, **Mignot E**, Nishino S (2001). CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. *Neurology*, 57: 2253-2258.
119. Hartwig G, Harsh J, Ripley R, Nishino S, **Mignot E** (2001). Low cerebrospinal fluid levels found in familial narcolepsy. *Sleep Med.*, 2(5): 451-453.
120. Okun M, Lin L, Pelin Z, Hong S, **Mignot E** (2002). Clinical and genetic aspects of narcolepsy-cataplexy across ethnic groups. *Sleep*, 25(1): 27-35.
121. Nishino S, Ripley B, **Mignot E**, Benson KL, Zarccone VP (2002). CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. *Psychiatry Res.*, 110(1): 1-7.
122. Hong S-C, Leen-Kim L, Park S-A, Han J-H, Lee S-P, Lin L, Okun M, Nishino S, **Mignot E** (2002). HLA and hypocretin studies in Korean patients with narcolepsy. *Sleep*, 25(4): 440-444.
123. Overeem S, van Hilten JJ, Ripley B, **Mignot E**, Nishino S, Lammers GJ (2002). Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. *Neurology*, 58: 498-499.

124. Shiba T, Ozu M, Yoshida Y, **Mignot E**, Nishino S (2002). Hypocretin stimulates [(35)S]GTPgammaS binding in Hcrtr 2-transfected cell lines and in brain homogenate. *Biochem. Biophys. Res. Commun.*, 294(3): 615-620.
125. Voderholzer U, Riemann D, Gann H, Hornyak M, Juengling F, Schumacher M, Reincke M, von Herbay A, Nishino S, **Mignot E**, Berger M, Lieb K (2002). Transient total sleep loss in a patient with cerebral Whipple's disease: a longitudinal study. *J. Sleep Res.*, 11(4): 321-329.
126. Allen RP, **Mignot E**, Ripley B, Nishino S, Earley CJ (2002). Increased CSF hypocretin-1 (orexin-A) in restless leg syndrome. *Neurology*, 59(4): 639-641.
127. Merikangas K, Chakravarti A, Moldin S, Araj H, Blangero J, Burmeister M, Crabbe J, Depaulo J, Foulks E, Freimer N, Koretz D, Lichtenstein W, **Mignot E**, Reiss A, Risch N, S Takahashi J (2002). Future of genetics of mood disorders research. *Biol. Psychiatry*, 52(6): 457.
128. Lin L, Wisor J, Shiba T, Taheri S, Yanai K, Wurts S, Lin X, Vitaterna M, Takahashi J, Loveberg TW, Koehl M, Uhl G, Nishino S, **Mignot E** (2002). Measurement of hypocreto/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time, age and genetic background. *Peptides*, 23(12): 2203-2211.
129. **Mignot E**, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, Vankova J, Black J, Harsh J, Bassetti C, Schrader H, Nishino S (2002). The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. *Arch. Neurol.*, 59(10): 1553-1562.
130. Bassetti C, Gugger M, Bischof M, Mathis J, Sturzenegger C, Werth E, Radanov B, Ripley B, Nishino S, **Mignot E** (2002). The Narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). *Sleep Med.*, 4(1) 7-12.
131. Pedrazzoli M, Ling Lin, Young TB, Finn L, Tufik S, **Mignot E** (2002). Effect of the prion 129 polymorphism on nocturnal sleep and insomnia complaints: a population-based study. *J. Sleep Res.*, (4): 357-358.
132. Fujiki N, Morris L, **Mignot E**, Nishino S (2002). Analysis of onset location, laterality and propagation of cataplexy in canine narcolepsy. *Psychiatry of Clinical Neuroscience*, 56(3): 275-276.
133. Overeem S, Steens SCA, Good CD, Ferrari MD, **Mignot E**, Frackowiak RSJ, van Buchem MA, Lammers GJ (2003). Voxel-based morphometry in hypocretin-deficient narcolepsy. *Sleep*, 26(1): 44-46.
134. Zeitzer J, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, **Mignot E** (2003). Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. *J. Neurosci.*, 23(8): 3555-3560.
135. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, Nishino S, **Mignot E** (2003). Diurnal variation of CSF hypocretin-1 (orexin-A) levels in control and depressed subjects. *Biol. Psychiatry*, 54: 96-104.
136. Dauvilliers Y, Carlander B, Molinari N, Desautels A, Okun M, Tafti M, Montplaisir J, **Mignot E**, Billiard M (2003). Month of birth as a risk factor for narcolepsy. *Sleep*, 26(6): 663-665.
137. Overeem S, Dalmau J, Bataller L, Nishino S, **Mignot E**, Verschuuren J, Lammers GJ (2003). Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. *Neurology*, 62(1): 138-140.

138. Martinez-Rodriguez, JE, Lin, L, Iranzo, A, Genis, D, Marti, MJ, Santamaria, J, **Mignot, E** (2003). Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. *Sleep*, 26 (3): 287-290.
139. Schenck, CH, Bundlie, SR, **Mignot, E**, Mahowald, MW (2003). Normal hypocretin-1 (orexin-A) cerebrospinal fluid level in a previously reported case of severe, life-long insomnia with motor hyperactivity. *Sleep Med.*, 4(3): 251.
140. Vankova J, Stepanova I, Jech R, Elleder M, Ling L, **Mignot E**, Nishino S, Nevsimalova S (2003). Sleep disturbances and hypocretin deficiency in Niemann-Pick Disease Type C. *Sleep*, 26 (4): 427-430.
141. Nishino S, Kanbayashi T, Fujiki N, Uchino M, Ripley B, Watanabe M, Lammers GJ, Ishiguro H, Shoji S, Nishida Y, Overeem S, Toyoshima I, Yoshida Y, Shimizu T, Taheri S, **Mignot E** (2003). CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. *Neurology*, 61: 823-825.
142. Hecht M, Lin L, Kushida CA, Umetsu DT, Taheri S, Einen M, **Mignot E** (2003). Report of a case of Immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin deficiency/narcolepsy. *Sleep*, 26(7): 809-810.
143. Stiasny-Kolster K, **Mignot E**, Lin L, Moller JC, Cassel W, Oertel WH (2003). CSF hypocretin-1 levels in restless legs syndrome. *Neurology*, 61(10): 1426-1429.
144. Martinez-Rodriguez JE, Sanchez-Valle R, Saiz A, Lin L, Iranzo A, **Mignot E**, Santamaria J (2003). Normal Hypocretin-1 levels in cerebrospinal fluid of patients with fatal familial insomnia. *Sleep*, 26(8): 1068.
145. Marcus CL, **Mignot E** (2003). Letter to the editor regarding the previous publication: "Secondary narcolepsy in children with brain tumors," *Sleep* 2002; 25:435-439. *Sleep*, 26(2): 228.
146. Fujiki N, Yoshida Y, Ripley B, **Mignot E**, Nishino S (2003). Effects of IV and ICV hypocretin-1 (Orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. *Sleep*, 26(8): 953-959.
147. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, **Mignot E**, Shiromani PJ (2003). Relationship between CSF hypocretin levels and hypocretin neuronal loss. *Exp. Neurol.*, 184(2): 1010-1016.
148. Gottlieb DJ, DeStefano AL, Foley DJ, **Mignot E**, Redline S, Givelber RJ, Young TB (2003). APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: The Sleep Heart Health Study. *Neurology*, 63(4): 664-668.
149. Schatzberg SJ, Cutter-Schatzberg K, Nydam D, Barrett J, Penn R, Flanders J, deLahunta A, Lin L, **Mignot E** (2003). Case study: The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. *J. Vet. Intern. Med.*, 18(4): 586-588.
150. Oksenberg JR, Barcellos LF, Cree BAC, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, **Mignot E**, Lin L, Goodin D, Erlich HA, Schmid S, Thomson G, Reich DE, Pericak-Vance MA, Haines JL, Hauser SL (2004). Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. *Am. J. Hum. Genet.*, 74(1): 160-167.

151. Castillo PR, **Mignot E**, Woodruff BK, Boeve BF (2004). Undetectable CSF hypocretin-1 in "Hashimoto's encephalopathy" associated with hypersomnolence and coma *Neurology*. *Neurology*, 62:1909.
152. Okura M, Fujiki N, Kita I, Honda K, Yoshida Y, **Mignot E**, Nishino S (2004). The roles of midbrain and diencephalic dopamine cell groups in the regulation of cataplexy in narcoleptic Dobermans. *Neurobiol. Dis.*, 16(1): 274-282.
153. Zeitzer JM, Buckmaster CL, Lyons DM, **Mignot E** (2004). Locomotor-dependent and independent components to hypocretin-1 (orexin A) regulation in a sleep/wake consolidating monkey. *J. Physiol. (London)*, 557(Pt3): 1045-1053.
154. Zhang S, Zeitzer JM, Yoshida Y, Wisor JP, Nishino S, Edgar DM, **Mignot E** (2004). Lesions suprachiasmatic nucleus eliminate daily rhythm of hypocretin-1 release. *Sleep*, 27(4): 619-627.
155. Martins PJ, D'Almeida V, Pedrazzoli M, Lin L, **Mignot E**, Tufik S (2004). Increased hypocretin-1 (orexin-a) levels in cerebrospinal fluid of rats after short-term forced activity. *Regul. Pept.*, 117(3): 155-158.
156. Pedrazzoli M, D'Almeida V, Martins PJ, Machado RB, Ling L, Nishino S, Tufik S, **Mignot E** (2004). Increased hypocretin-1 levels in cerebrospinal fluid after REM sleep deprivation. *Brain Res.*, 995(1): 1-16.
157. Desarnaud F, Murillo-Rodriguez E, Lin L, Xu M, Gerashchenko D, Nishino S, **Mignot E**, Shiromani PJ (2004). The diurnal rhythm of hypocretin in young and old F344 rats. *Sleep*, 27(5): 851-856.
158. Fromherz S, **Mignot E** (2004). Narcolepsy research: past, present, and future perspectives. *Arch. Ital. Biol.*, 142(4): 479-486.
159. Okun ML, Giese S, Lin L, Einen M, **Mignot E**, Coussons-Read ME (2004). Exploring the cytokine and endocrine involvement in narcolepsy. *Brain Behav. Immun.*, 18(4): 326-332.
160. Lin L, Finn L, Zhang J, Young T, **Mignot E** (2004). Angiotensin-converting enzyme, sleep disordered breathing, and hypertension. *Am. J. Respir. Crit. Care Med.*, 170(12): 1349-1353.
161. Taheri S, Lin L, Austin D, Young T, **Mignot E** (2004). Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. *PloS Medicine*, (3): e68, 1-8.
162. Lin L, Finn L, Zhang J, Young T, **Mignot E** (2004). The angiotensin-converting enzyme, sleep-disordered breathing, and hypertension. *Am. J. Respir. Crit. Care Med.*, 170: 1349-1353.
163. Picchioni D, **Mignot E**, Harsh JR (2004). The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1 *0602. *Sleep*, 27(8): 1471-1475.
164. **Mignot E** (2004). A year in review—basic science, narcolepsy, and sleep in neurologic diseases. *Sleep*, 27(6): 1209-1212.
165. **Mignot E** (2004). An update on the pharmacotherapy of excessive daytime sleepiness and cataplexy. *Sleep Med.*, 8(5): 333-338.
166. Baumann CR, Dauvilliers Y, **Mignot E**, Bassetti CL (2004). Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. *Eur. Neurol.*, 52(2): 73-76.
167. Baumann CR, Stocker R, Imhof HG, Trentz O, Hersberger M, **Mignot E**, Bassetti CL (2005). Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. *Neurology*, 65(1): 147-149.

168. Philipp U, Hamann H, Mecklenburg L, Nishino S, **Mignot E**, Gunzel-Apel AR, Schmutz SM, Leeb T (2005). Polymorphisms within the canine MLPH gene are associated with dilute coat color in dogs. *BMC Genet.*, (6): 34.
169. Nevsimalova S, Vankova J, Stepanova I, Seemanova E, **Mignot E**, Nishino S (2005). Hypocretin deficiency in Prader-Willi Syndrome. *European Journal of Neurology*, (1): 70-72.
170. Crocker A, Espanan RA, Papadopoulou M, Saper CB, Faraco J, Sakurai T, Honda M, **Mignot E**, Scammell TE (2005). Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. *Neurology*, 65(8):1184-8.
171. Tachibana N, Taniike M, Okinaga T, Ripley B, **Mignot E**, Nishino S (2005). Hypersomnolence and increased REM sleep with low cerebrospinal fluid hypocretin level in a patient after removal of craniopharyngioma. *Sleep Med.*, 6(6):567-9.
172. Chen W, Black J, Call P, **Mignot E** (2005). Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. *Ann. Neurol.* (letter), 58(3):489-90.
173. Larkin EK, Patel SR, Redline S, **Mignot E**, Elston RC, Hallmayer J (2005). Apolipoprotein E and obstructive sleep apnea: evaluating whether a candidate gene explains a linkage peak. *Genet Epidemiol.* 30(2):101-10.
174. Plazzi G, Parmeggiani A, **Mignot E**, Lin L, Scano MC, Posar A, Bernardi F, Lodi R, Tonon C, Barbiroli B, Montagna P, Cicognani A (2006). Narcolepsy-cataplexy associated with precocious puberty. *Neurology*, 66:1577-1579.
175. **Mignot E**, Lin L, Finn L, Lopes C, Pluff K, Sundstrom ML, Young T (2006). Correlates of sleep onset REM Periods during the Multiple Sleep Latency Test in community adults. *Brain*, 129(pt 6): 1609-23.
176. Hong SC, Lin L, Jeong JH, Shin YK, Han JH, Lee JH, Lee SP, Zhang J, Einen M, **Mignot E** (2006). A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. *Sleep*; 29(11):1429-38.
177. Arnulf I, Lin L, Zhang J, Russel IJ, Ripley B, Einen E, Nevsimalova S, Bassetti C, Bourgin P, Nishino S, **Mignot E** (2006). CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency? *Sleep*, 29(8):1017-24.
178. Ferri R, Zucconi M, Manconi M, Bruni O, Ferini-Strambi L, Vandi S, Montagna P, **Mignot E**, Plazzi G (2006) Different Periodicity and Time Structure of Leg Movements during Sleep in Narcolepsy/Cataplexy and Restless Legs Syndrome, *Sleep*, ;29(12):1587-94.
179. Hong S, Lin L, Lo B, Jeong J, Shin YK, Kim SY, Kweon Y, Zhang J, Einen, M, Smith A, Hansen J, Grument C, **Mignot E** (2006) DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans, *Hum. Immunol.*, 68(1):59-68.
180. Renier C, Faraco J, Bourgin P, Rosa F, **Mignot E** (2007). Conservation of sedative-hypnotic effects and corresponding genomic targets in *Danio rerio*: Genomic and functional conservation of sedative-hypnotic targets in the zebrafish. *Pharmacogenet. Genomics*, 17(4):237-53.
181. Rubio JP, Stankovich J, Brufoot RK, Johnson LJ, Huxtable SJ, Butzkueven H, Lin L, Taylor VB, Speed TP, Kiopatrik TJ, **Mignot E** Foote SJ (2007) Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients *Immunogenetics*, 59(3):177-86.

182. Taiwo OB, Russell IJ, **Mignot E**, Lin L, Michalek JE, Haynes W, Xiao Y, Zeitzer JM, Larson AA. Normal cerebrospinal fluid levels of hypocretin-1 (orexin A) in patients with fibromyalgia syndrome. *Sleep Med.*, 8(3):260-5.
183. Friedman LF, Zeitzer JM, Lin L, Hoff D, **Mignot E**, Peskind ER, Yesavage JA (2007). In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. *Neurology* 68:793-794.
184. Zhang S, Zeitzer JM, Sakurai T, Nishino S, **Mignot E** (2007) Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy. *J. Physiol. (London)*, 581(Pt 2):649-63
185. Patel SR, Emma KL, **Mignot E**, Lin L, Redline S (2007). The association of angiotensin converting enzyme (ACE) polymorphisms with sleep apnea and hypertension. *Sleep*, 30(4):531-3.
186. Lindberg J, Saetre P, Nishino S, **Mignot E**, Jazin E (2007). Reduced expression of TAC1, PENK and SOCS2 in Hcrtr-2 mutated narcoleptic dog brain. *BMC Neurosci.* 8:34-37.
187. Ferri R, Zucconi M, Manconi M, Bruni O, Ferini-Strambi L, Vandi S, Montagna P, **Mignot E**, Plazzi G (2006). Different periodicity and time structure of leg movements during sleep in narcolepsy/cataplexy and restless legs syndrome. *Sleep*, 29(12):1587-94.
188. Nevsimalova S, Prihodva I, Kemlink D, Lin L, **Mignot E**, (2007) REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy. *Sleep Med.*, 8(7-8):784-6.
189. Szklo-Coxe M, Young T, Finn L, **Mignot E** (2007). Depression: Relationships to sleep paralysis and other sleep disturbances in a community sample. *J. Sleep Res, Sep*;16(3):297-312.
190. Appelbaum L, Skariah G, Mourrain, P, **Mignot E**, (2007) Comparative expression of p2rx receptors and ecto-nucleoside triphosphate diphosphohydrolase 3 in hypocretin and sensory neurons in zebrafish. *Brain Research, Oct12*;1174:66-75.
191. Taheri S, Austin D, Lin L, Nieto FJ, Young T, **Mignot E** (2007) Correlates of serum C-reactive protein (CRP)—no association with sleep duration or sleep disordered breathing. *Sleep* Aug 1;20(8):991-6.
192. Zeitzer JM, Buckmaster CL, Lyons DM, **Mignot E**, (2007) Increasing length of wakefulness and modulation of hypocretin-1 in the wake-consolidated squirrel monkey. *Am J Physiol Regul Integr Comp Physiol* Oct;293(4):R1736-42.
193. Yokogawa T, Marin W, Faraco J, Pezeron G, Appelbaum L, Rosa F, Mourrain P, **Mignot E**. (2007) Characterization of sleep in zebrafish and insomnia in hypocretin receptor mutants. *PLoS Biol.*, Oct 16;5(10):e277.
194. Ciafaloni E, **Mignot E**, Sansone V, Hilbert JE, Lin L, Lin X, Liu LC, Pigeon WR, Perlis ML, Thornton CA (2008). The hypocretin neurotransmission system in myotonic dystrophy type 1. *Neurology* 70(3):226-30.
195. Colas D, Valletta JS, Takimoto-Kimura R, Nishino S, Fujiki N, Mobley WC, **Mignot E** (2008). Sleep and EEG features in genetic models of Down syndrome. *Neurobiol Dis.* 30(1):1-7
196. Serra L, Montagna P, **Mignot E**, Lugaresi E, Plazzi G (2008). Cataplexy features in childhood narcolepsy. *Mov Disord*, 23(6):858-65
197. Eriksson KS, Zhang S, Lin L, Larivière RC, Julien JP, **Mignot E**. The type III neurofilament peripherin is expressed in the tuberomammillary neurons of the mouse. *BMC Neurosci.* 2008 Feb 24;9:26.

198. Arnulf I, Lin L, Gadoth N, File J, Lecendreux M, Franco P, Zeitzer J, Lo B, Faraco, JH, **Mignot E** (2008). Kleine-Levin syndrome: a systematic study of 108 patients. *Ann. Neurol.*, 63(4):482-93.
199. Mishima, K, Fujjuki N, Yoshida Y, Sakurai R, Honda M, **Mignot E**, Nishino, S (2008). Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. *Sleep*, 31(8):1119-26.
200. Alaez C, Lin L, Flores-A H, Vazquez M, Munguia A, **Mignot E**, Haro R, Baker H, Gorodezky C (2008). Association of narcolepsy-cataplexy with HLA-DRB1 and DQB1 in Mexican patients: a relationship between HLA and gender is suggested. *BMC Med Genet.* Aug 15;9:79.
201. Donadio V, Plazzi G, Vandi S, Franceschini C, Karlsson T, Montagna P, Vetrugno R, Bugiardini E, **Mignot E**, Liguori R (2008). Sympathetic and cardiovascular activity during cataplexy in narcolepsy. *J Sleep Res.* 17(4):458-63.
202. Miyagawa T, Kawashima M, Nishida N, Ohashi J, Kimura R, Fujimoto A, Shimada M, Morishita S, Shigeta T, Lin L, Hong SC, Faraco J, Shin YK, Jeong JH, Okazaki Y, Tsuji S, Honda M, Honda Y, **Mignot E**, Tokunaga K (2008). Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. *Nat Genet* 40(11):1324-8.
203. Plazzi G, Poli F, Franceschini C, Parmeggiani A, Pirazzoli P, Bernardi F, **Mignot E**, Cicognani A, Montagna P (2008). Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. *J Neurol.* 255(10):1549-54.
204. Honda M, Eriksson KS, Zhang S, Tanaka S, Lin L, Salehi A, Hesla PE, Maehlen J, Gaus SE, Yanagisawa M, Sakurai T, Taheri S, Tsuchiya K, Honda Y, **Mignot E** (2009). IGFBP3 colocalizes with and regulates hypocretin (orexin). *PLoS ONE.* 4(1):e4254.
205. Nishino S, Sakurai E, Nevsimalova S, Yoshida Y, Watanabe T, Yanai K, **Mignot E**. (2009). Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. *Sleep* 32(2):175-80.
206. Scammell TE, Willie JT, Guilleminault C, Siegel JM, International Working Group on Rodent Models of Narcolepsy. (2009). A consensus definition of cataplexy in mouse models of narcolepsy. *Sleep.* 2009 32(1):111 -6.
207. Hallmayer J, Faraco J, Lin L, Hesselson S, Winklemann J, Kawashima M, Mayer G, Plazzi G, Nevsimalova S, Bourgin P, Hong S, Honda Y, Honda M, Högl B, Longstreth Jr WT, Montplaisir J, Kemlink D, Einen M, Chen J, Musone SL, Akana M, Miyagawa T, Duan J, Desautels A, Erhardt C, Hesla PE, Poll F, Frauscher B, Jeong JH, Sung-Pil Lee SP, Ton TGN, Kvale M, Kolesar LB, Dobrovolska M, Nepom GT, Salomon D, Wichmann HE, Rouleau GA, Gieger C, Levinson DF, Gejman PV, Meitinger T, Young T, Peppard P, Tokunaga K, Kwock PY, Risch N, **Mignot E**. (2009). Narcolepsy is strongly associated with the TCR alpha locus. *Nature Genet*, 41(6):708-11.
208. Tonon C, Franceschini C, Testa C, Manners DN, Poli F, Mostacci B, **Mignot E**, Montagna P, Barbiroli B, Lodi R, Plazzi G (2009). Distribution of neurochemical abnormalities in patients with narcolepsy with cataplexy: An in vivo brain proton MR spectroscopy study. *Brain Res Bull.* 80(3):147-50.

209. Goel N, Banks S, **Mignot E**, Dinges DF (2009). PER3 polymorphism predicts cumulative sleep homeostatic but not neurobehavioral changes to chronic partial sleep deprivation. *PLoS One* 4(6):e5874.
210. Honda M, Arai T, Fukazawa M, Honda Y, Tsuchiya K, Salehi A, Akiyama H, **Mignot E** (2009). Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy. *Neurology* 73(7):511-7.
211. Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, Zeitzer J, **Mignot E** (2009). Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. *Sleep* 32:979-983.
212. Zeitzer JM, Buckmaster CL, Landolt HP, Lyons DM, **Mignot E** (2009). Modafinil and gamma-hydroxybutyrate have sleep state-specific pharmacological actions on hypocretin-1 physiology in a primate model of human sleep. *Behav Pharmacol.* Oct;20(7):643-52.
213. Berman JR, Skariah G, Maro GS, **Mignot E**, Mourrain P (2009). Characterization of two melanin-concentrating hormone genes in zebrafish reveals evolutionary and physiological links with the mammalian MCH system. *J Comp Neurol.*;517(5):695-710.
214. Vetrugno R, D'Angelo R, Moghadam KK, Vandi S, Franceschini C, Mignot E, Montagna P, Plazzi G Behavioural and neurophysiological correlates of human cataplexy: A video-polygraphic study *Clinical Neurophysiology*, in press.
215. Eriksson KS, **Mignot E** (2009). The homeobox gene T-box 3 is expressed in the mouse hypothalamus and medulla. *Brain Res*, Dec 11;1302:233-9.
216. Poli F, Plazzi G, Di Dalmazi G, Ribichini D, Vicennati V, Pizza F, **Mignot E**, Montagna P, Pasquali R, Pagotto U (2009). Body mass index-independent metabolic alterations in narcolepsy with cataplexy. *Sleep*. 2009 Nov 1;32(11):1491-7.
217. Vetrugno R, D'Angelo R, Moghadam KK, Vandi S, Franceschini C, **Mignot E**, Montagna P, Plazzi G (2010). Behavioural and neurophysiological correlates of human cataplexy: a video-polygraphic study. *Clin Neurophysiol.* 2010;121(2):153-62
218. Appelbaum L, Wang GX, Maro GS, Mori R, Tovin A, Marin W, Yokogawa T, Kawakami K, Smith SJ, Gothilf Y, **Mignot E**, Mourrain P (2009). Sleep-wake regulation and hypocretin-melatonin interaction in zebrafish. *Proc Natl Acad Sci U S A*;106(51):21942-7.
219. Han F, **Mignot E**, Wei YC, Dong SX, Li J, Lin L, An P, Wang LH, Wang JS, He MZ, Gao HY, Li M, Gao ZC, Strohl KP (2010). Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. *Eur Respir J.* ;36(3):577-83.
220. Plazzi G, Tonon C, Rubboli G, Poli F, Franceschini C, Pizza F, Bisulli A, Rizzo G, **Mignot E**, Montagna P, Lodi R (2010). Narcolepsy with cataplexy associated with holoprosencephaly misdiagnosed as epileptic drop attacks. *Mov Disord*; 25(6):780-2. Erratum in: *Mov Disord.* 2010 Aug 15;25(11):1764.
221. Kawashima M, Lin L, Tanaka S, Jennum P, Knudsen S, Nevsimalova S, Plazzi G, **Mignot E** (2010). Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. *Sleep* 33(7):869-74.
222. Schwimmer H, Stauss HM, Abboud F, Nishino S, **Mignot E**, Zeitzer JM (2010). Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins *J Appl Physiol*;109(4):1053-63.

223. Aran A, Weiner K, Lin L, Finn LA, Greco MA, Peppard P, Young T, Ofran Y, **Mignot E** (2010). Post-streptococcal auto-antibodies inhibit protein disulfide isomerase and are associated with insulin resistance. *PLoS One*, Sep 23;5(9):e12875.
224. Appelbaum L, Wang G, Yokogawa T, Skariah GM, Smith SJ, Mourrain P, **Mignot E** (2010). Circadian and homeostatic regulation of structural synaptic plasticity in hypocretin neurons. *Neuron*, 68(1):87-98.
225. Goel N, Banks S, **Mignot E**, Dinges DF (2010). DQB1*0602 predicts interindividual differences in physiologic sleep, sleepiness, and fatigue. *Neurology*. 75(17):1509-19.
226. Tanaka S, Kodama T, Nonaka T, Toyoda H, Arai M, Fukazawa M, Honda Y, Honda M, **Mignot E** (2010). Transcriptional regulation of the hypocretin/orexin gene by NR6A1. *Biochem Biophys Res Commun*. 403(2):178-83.
227. Dauvilliers Y, Montplaisir J, Cochen V, Desautels A, Einen M, Lin L, Kawashima M, Bayard S, Monaca C, Tiberge M, Filipini D, Tripathy A, Nguyen BH, Kotagal S, **Mignot E** (2010). Post-H1N1 narcolepsy-cataplexy. *Sleep*; 33(11):1428-30.
228. Aran A, Einen M, Lin L, Plazzi G, Nishino S, **Mignot E** (2010). Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. *Sleep*;33(11):1457-64.
229. Kornum BR, Kawashima M, Faraco J, Lin L, Rico TJ, Hesselson S, Axtell RC, Kuipers H, Weiner K, Hamacher A, Kassack MU, Han F, Knudsen S, Li J, Dong X, Winkelmann J, Plazzi G, Nevsimalova S, Hong SC, Honda Y, Honda M, Högl B, Ton TG, Montplaisir J, Bourgin P, Kemlink D, Huang YS, Warby S, Einen M, Eshragh JL, Miyagawa T, Desautels A, Ruppert E, Hesla PE, Poli F, Pizza F, Frauscher B, Jeong JH, Lee SP, Strohl KP, Longstreth WT Jr, Kvale M, Dobrovolna M, Ohayon MM, Nepom GT, Wichmann HE, Rouleau GA, Gieger C, Levinson DF, Gejman PV, Meitinger T, Peppard P, Young T, Jennum P, Steinman L, Tokunaga K, Kwok PY, Risch N, Hallmayer J, **Mignot E** (2011). *Nat Genet*. 2011 Jan;43(1):66-71.
230. Zeitzer JM, Fasicaro RA, Grove ME, **Mignot E**, Yesavage JA, Friedman L (2011). Faster REM sleep EEG and worse restedness in older insomniacs with HLA DQB1*0602. *Psychiatry Res*. 2011 Feb 1 [Epub ahead of print]
231. Vardeny O, Peppard PE, Finn LA, Faraco JH, **Mignot E**, Hla KM (2011). β 2 adrenergic receptor polymorphisms and nocturnal blood pressure dipping status in the Wisconsin Sleep Cohort Study. *J Am Soc Hypertens*. 5(2):114-22.
232. Palaia V, Poli F, Pizza F, Antelmi E, Franceschini C, Moghadam KK, Provini F, Pagotto U, Montagna P, Schenck CH, **Mignot E**, Plazzi G. Narcolepsy with cataplexy associated with nocturnal compulsive behaviors: a case-control study. *Sleep*. 2011 Oct 1;34(10):1365-71.
233. Zeitzer JM, Kodama T, Buckmaster CL, Honda Y, Lyons DM, Nishino S, **Mignot E**. Time-course of cerebrospinal fluid histamine in the wake-consolidated squirrel monkey. *J Sleep Res*. 2011 Sep 13. doi: 10.1111/j.1365-2869.2011.00957. [Epub ahead of print]
234. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, An P, Zhao L, Wang LH, Li QY, Yan H, Gao ZC, Yuan Y, Strohl KP, **Mignot E**. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. *Ann Neurol*. 2011 Sep;70(3):410-7.

235. Winkelmann J, Czamara D, Schormair B, Knauf F, Schulte EC, Trenkwalder C, Dauvilliers Y, Polo O, Högl B, Berger K, Fuhs A, Gross N, Stiasny-Kolster K, Oertel W, Bachmann CG, Paulus W, Xiong L, Montplaisir J, Rouleau GA, Fietze I, Vávrová J, Kemlink D, Sonka K, Nevsimalova S, Lin SC, Wszolek Z, Vilariño-Güell C, Farrer MJ, Gschliesser V, Frauscher B, Falkenstetter T, Poewe W, Allen RP, Earley CJ, Ondo WG, Le WD, Spieler D, Kaffe M, Zimprich A, Kettunen J, Perola M, Silander K, Cournu-Rebeix I, Francavilla M, Fontenille C, Fontaine B, Vodicka P, Prokisch H, Lichtner P, Peppard P, Faraco J, **Mignot E**, Gieger C, Illig T, Wichmann HE, Müller-Myhsok B, Meitinger T. Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. *PLoS Genet*. 2011 Jul;7(7):e1002171. Epub 2011 Jul 14.
236. Han F, Lin L, Li J, Aran A, Dong SX, An P, Zhao L, Li M, Li QY, Yan H, Wang JS, Gao HY, Li M, Gao ZC, Strohl KP, **Mignot E**. Presentations of primary hypersomnia in Chinese children. *Sleep*. 2011 May 1;34(5):627-32.
237. Palaia V, Poli F, Pizza F, Antelmi E, Franceschini C, Moghadam KK, Provini F, Pagotto U, Montagna P, Schenck CH, **Mignot E**, Plazzi G. Narcolepsy with cataplexy associated with nocturnal compulsive behaviors: a case-control study. *Sleep*. 2011 Oct 1;34(10):1365-71.
238. Plazzi G, Pizza F, Palaia V, Franceschini C, Poli F, Moghadam KK, Cortelli P, Nobili L, Bruni O, Dauvilliers Y, Lin L, Edwards MJ, **Mignot E**, Bhatia KP. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. *Brain*. 2011 Dec;134(Pt 12):3480-92. doi: 10.1093/brain/awr244. Epub 2011 Sep 19.
239. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, An P, Zhao L, Wang LH, Li QY, Yan H, Gao ZC, Yuan Y, Strohl KP, **Mignot E**. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. *Ann Neurol*. 2011 Sep;70(3):410-7.
240. Winkelmann J, Lin L, Schormair B, Kornum BR, Faraco J, Plazzi G, Melberg A, Cornelio F, Urban AE, Pizza F, Poli F, Grubert F, Wieland T, Graf E, Hallmayer J, Strom TM, **Mignot E**. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. *Hum Mol Genet*. 2012 May 15;21(10):2205-10.
241. Han F, Lin L, Li J, Dong SX, An P, Zhao L, Liu NY, Li QY, Yan H, Gao ZC, Faraco J, Strohl KP, Liu X, Miyadera H, **Mignot E**. HLA-DQ association and allele competition in Chinese narcolepsy. *Tissue Antigens*. 2012 Oct;80(4):328-35.
242. Han F, Lin L, Li J, Dong XS, **Mignot E**. Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. *Ann Neurol*. 2012 Nov 9. doi: 10.1002/ana.23799.
243. Andlauer O, Moore H 4th, Hong SC, Dauvilliers Y, Kanbayashi T, Nishino S, Han F, Silber MH, Rico T, Einen M, Kornum BR, Jennum P, Knudsen S, Nevsimalova S, Poli F, Plazzi G, **Mignot E**. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. *Sleep*. 2012 Sep 1;35(9):1247-55F.
244. Andlauer O, Moore H, Jouhier L, Drake C, Peppard PE, Han F, Hong SH, Poli F, Plazzi G, O'Hara R, Haffen E, Roth T, Young T, **Mignot E**. Nocturnal REM sleep latency for identifying patients with narcolepsy/hypocretin deficiency. *JAMA Neurol*. 2013 Jul;70(7):891-902

245. Pedroso JL, Barsottini OGP, Lin L, Melberg A, Oliveira ASB, **Mignot E**. A Novel de novo Exon 21 DNMT1 Mutation Causes Cerebellar Ataxia, Deafness and Narcolepsy in a Brazilian Patient. *Sleep*, Aug 1;36(8):1257-9.
246. Faraco J, Lin L, Kornum BK, Kenny EE, Trynka G, Einen M, Rico TJ, Lichtner P, Dauvilliers Y, Arnulf I, Lecendreux M, Javidi S, Geisler P, Mayer G, Pizza F, Poli F, Plazzi G, Overeem S, Lammers GJ, Kemlink D, Sonka K, Nevsimalova S, Rouleau G, Desautels A, Montplaisir J, Frauscher B, Ehrmann L, Högl B, Jennum P, Bourgin P, Peraita-Adrados R, Iranzo A, Bassetti C, Chen WM, Concannon P, Thompson SD, Damotte V, Fontain B, Breban M, Gieger C, Klopp N, Deloukas P, Wijmenga C, Hallmayer J, Onengut-Gumuscu S, Rich SS, Winkelmann J, **Mignot E**. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. *Plos Genetics*, PLoS Genet. 2013;9(2):e1003270.
247. Khor SS, Miyagawa T, Toyoda H, Yamasaki M, Kawamura Y, Tani H, Okazaki Y, Sasaki T, Lin L, Faraco J, Rico T, Honda Y, Honda M, **Mignot E**, Tokunaga K. Genome-wide association study of HLA-DQB1*06:02 negative essential hypersomnia. *PeerJ*. 2013 Apr 16;1:e66.
248. Dong XS, Ma SF, Cao CW, Li J, An P, Zhao L, Liu NY, Yan H, Hu QT, **Mignot E**, Strohl KP, Gao ZC, Zeng C, Han F. Hypocretin (orexin) neuropeptide precursor gene, HCRT, polymorphisms in early-onset narcolepsy with cataplexy. *Sleep Med*. 2013 Jun;14(6):482-7.
249. Poli F, Pizza F, **Mignot E**, Ferri R, Pagotto U, Taheri S, Finotti E, Bernardi F, Pirazzoli P, Cicognani A, Balsamo A, Nobili L, Bruni O, Plazzi G. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. *Sleep*. 2013 Feb 1;36(2):175-81.
250. Zhou X, Wang J, Zou H, Ward MM, Weisman MH, Espitia MG, Xiao X, Petersdorf E, **Mignot E**, Martin J, Gensler LS, Scheet P, Reveille JD. MICA, a gene contributing strong susceptibility to ankylosing spondylitis. *Ann Rheum Dis*. 2013 Jun 1. [Epub ahead of print].
251. Nikodemova M, Finn L, **Mignot E**, Salzieder N, Peppard PE. Association of Sleep Disordered Breathing and Cognitive Deficit in APOE ε4 Carriers. *Sleep*. 2013 Jun 1;36(6):873-80.
252. Pizza F, Vandi S, Poli F, Moghadam KK, Franceschini C, Bellucci C, Cipolli C, Ingravallo F, Natalini G, **Mignot E**, Plazzi G. Narcolepsy with cataplexy mimicry: the strange case of two sisters. *J Clin Sleep Med*. 2013 Jun 15;9(6):611-2.
253. Roth T, Dauvilliers Y, Mignot E, Montplaisir J, Paul J, Swick T, Zee P. Disrupted nighttime sleep in narcolepsy. *J Clin Sleep Med*. 2013 Sep;9(9):955-65. doi: 10.5664/jcsm.3004.
254. Valko PO, Gavrilov YV, Yamamoto M, Reddy H, Haybaeck J, Mignot E, Baumann CR, Scammell TE. Increase of histaminergic tuberomammillary neurons in narcolepsy. *Ann Neurol*. 2013 Dec;74(6):794-804. doi: 10.1002/ana.24019.
255. Gosal D, Ealing J, **Mignot E**. A mutation in the dnmt1 gene causing autosomal dominant ataxia with deafness and cataplexy. *J Neurol Neurosurg Psychiatry*. 2013 Nov;84(11):e2.
256. Pizza F, Franceschini C, Peltola H, Vandi S, Finotti E, Ingravallo F, Nobili L, Bruni O, Lin L, Edwards MJ, Partinen M, Dauvilliers Y, **Mignot E**, Bhatia KP, Plazzi G. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. *Brain*. 2013 Dec;136(Pt 12):3787-95. doi: 10.1093/brain/awt277.

257. Han F, Faraco J, Dong XS, Ollila HM, Lin L, Li J, An P, Wang S, Jiang KW, Gao ZX, Zhao L, Yan H, Liu, YN, Li QH, Zhang XZ, Hu Y, Wang JY, Lu YH, Lu CJ, Zhou W, Hallmayer J, Huang YS, Strohl KP, Pollmächer T, **Mignot E**. Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic. *PLoS Genet*. 2013 Oct;9(10):e1003880. doi: 10.1371/journal.pgen.1003880.
258. De la Herran-Arita AK, Kornum B, Mahlios J, Jiang W, Ling Lin L, Hou T, Macaubas C, Einen E, Plazzi G, Crowe C, Newell E, Davis M, Mellins E, **Mignot E**. T-cells cross-reactive to hypocretin and H1N1 influenza epitopes linked to narcolepsy outbreak. *Science Translational Medicine*, 2013 Dec 18;5(216):216ra176. doi: 10.1126/scitranslmed.3007762
259. Moore HE 4th, Andlauer O, Simon N, **Mignot E**. Exploring medical diagnostic performance using interactive, multi-parameter sourced receiver operating characteristic scatter plots. *Comput Biol Med*. 2014 Apr;47:120-9. doi: 10.1016/j.compbiomed.2014.01.012. Epub 2014 Feb 3.
260. Warby SC, Wendt SL, Welinder P, Munk EG, Carrillo O, Sorensen HB, Jennum P, Peppard PE, Perona P, **Mignot E**. Sleep-spindle detection: crowdsourcing and evaluating performance of experts, non-experts and automated methods. *Nat Methods*. 2014 Apr;11(4):385-92. doi: 10.1038/nmeth.2855. Epub 2014 Feb 23.
261. Moghadam KK, Pizza F, Tonon C, Lodi R, Carelli V, Poli F, Franceschini C, Barboni P, Seri M, Ferrari S, La Morgia C, Testa C, Cornelio F, Liguori R, Winkelmann J, Lin L, **Mignot E**, Plazzi G. Polysomnographic and neurometabolic features may mark preclinical autosomal dominant cerebellar ataxia, deafness, and narcolepsy due to a mutation in the DNA (cytosine-5-)-methyltransferase gene, DNMT1. *Sleep Med*. 2014 May;15(5):582-5. doi: 10.1016/j.sleep.2013.09.028. Epub 2014 Feb 12.
262. Moghadam KK, Pizza F, La Morgia C, Franceschini C, Tonon C, Lodi R, Barboni P, Seri M, Ferrari S, Liguori R, Donadio V, Parchi P, Cornelio F, Inzitari D, Mignarri A, Capocchi G, Dotti MT, Winkelmann J, Lin L, **Mignot E**, Carelli V, Plazzi G. Narcolepsy is a common phenotype in HSN IE and ADCA-DN. *Brain*. 2014 Jun;137(Pt 6):1643-55. doi: 10.1093/brain/awu069. Epub 2014 Apr 10.
263. Black J, Reaven NL, Funk SE, McGaughey K, Ohayon M, Guilleminault C, Ruoff C, **Mignot E**. The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings. *Sleep Med*. 2014 May;15(5):522-9. doi: 10.1016/j.sleep.2014.02.001. Epub 2014 Feb 15.
264. **Mignot EJ**. History of narcolepsy at Stanford University. *Immunol Res*. 2014 May;58(2-3):315-39. doi: 10.1007/s12026-014-8513-4. Review.
265. Baumann CR, **Mignot E**, Lammers GJ, Overeem S, Arnulf I, Rye D, Dauvilliers Y, Honda M, Owens JA, Plazzi G, Scammell TE. Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. *Sleep*. 2014 Jun 1;37(6):1035-42. doi: 10.5665/sleep.3756.
266. Goldbart A, Peppard P, Finn L, Ruoff CM, Barnet J, Young T, **Mignot E**. Narcolepsy and predictors of positive MSLTs in the Wisconsin Sleep Cohort. *Sleep*. 2014 Jun 1;37(6):1043-51. doi: 10.5665/sleep.3758.
267. De la Herrán-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L, Hou T, Macaubas C, Einen M, Plazzi G, Crowe C, Newell EW, Davis MM, Mellins ED, **Mignot E**. Retraction of the research article: "CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope

- in narcolepsy". *Sci Transl Med*. 2014 Jul 30;6(247):247rt1. doi:10.1126/scitranslmed.3009995. No abstract available.
268. Moore H 4th, Winkelmann J, Lin L, Finn L, Peppard P, **Mignot E**. Periodic leg movements during sleep are associated with polymorphisms in BTBD9, TOX3/BC034767, MEIS1, MAP2K5/SKOR1, and PTPRD. *Sleep*. 2014 Sep 1;37(9):1535-42. doi: 10.5665/sleep.4006. PMID:25142570.
269. Canellas F, Lin L, Julià MR, Clemente A, Vives-Bauza C, Ollila HM, Hong SC, Arboleya SM, Einen MA, Faraco J, Fernandez-Vina M, **Mignot E**. Dual cases of type 1 narcolepsy with schizophrenia and other psychotic disorders. *J Clin Sleep Med*. 2014 Sep 15;10(9):1011-8. doi:10.5664/jcsm.4040. PMID:25142772.
270. Han F, Lin L, Schormair B, Pizza F, Plazzi G, Ollila HM, Nevsimalova S, Jennum P, Knudsen S, Winkelmann J, Coquillard C, Babrzadeh F, Strom TM, Wang C, Mindrinos M, Fernandez Vina M, **Mignot E**. HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency. *Sleep*. 2014 Oct 1;37(10):1601-8. doi: 10.5665/sleep.4066. PMID:25197808
271. Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, **Mignot E**, De Wals P. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. *PLoS One*. 2014 Sep 29;9(9):e108489. doi: 10.1371/journal.pone.0108489. eCollection 2014. PMID:25264897.
272. Pizza F, Vandi S, Liguori R, Parchi P, Avoni P, **Mignot E**, Plazzi G. Primary progressive narcolepsy type 1: the other side of the coin. *Neurology*. 2014 Dec 2;83(23):2189-90. doi: 10.1212/WNL.0000000000001051. Epub 2014 Oct 29. No abstract available. PMID:25355832.
273. Wendt SL, Welinder P, Sorensen HB, Peppard PE, Jennum P, Perona P, **Mignot E**, Warby SC. Inter-expert and intra-expert reliability in sleep spindle scoring. *Clin Neurophysiol*. 2015 Aug;126(8):1548-56. doi: 10.1016/j.clinph.2014.10.158. Epub 2014 Nov 10. PMID:25434753
274. Ollila HM, Fernandez-Vina M, **Mignot E**. HLA-DQ allele competition in narcolepsy: a comment on Tafti et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. *Sleep*. 2015 Jan 1;38(1):147-51. doi: 10.5665/sleep.4342. PMID:25325462.
275. Moore H 4th, Leary E, Lee SY, Carrillo O, Stubbs R, Peppard P, Young T, Widrow B, **Mignot E**. Design and validation of a periodic leg movement detector. *PLoS One*. 2014 Dec 9;9(12):e114565. doi: 10.1371/journal.pone.0114565. eCollection 2014. PMID:25489744.
276. Jacob L, Leib R, Ollila HM, Bonvalet M, Adams CM, **Mignot E**. Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. *Brain Behav Immun*. 2015 Jul;47:44-57. doi: 10.1016/j.bbi.2014.11.004. Epub 2014 Nov 15. PMID:25452148.
277. Ollila HM, Ravel JM, Han F, Faraco J, Lin L, Zheng X, Plazzi G, Dauvilliers Y, Pizza F, Hong SC, Jennum P, Knudsen S, Kornum BR, Dong XS, Yan H, Hong H, Coquillard C, Mahlios J, Jolanki O, Einen M, Arnulf I, Högl B, Frauscher B, Crowe C, Partinen M, Huang YS, Bourgin P, Vaarala O, Désautels A, Montplaisir J, Mack SJ, Mindrinos M, Fernandez-Vina M, **Mignot E**. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. *Am J Hum Genet*. 2015 Jan 8;96(1):136-46. doi: 10.1016/j.ajhg.2014.12.010. Erratum in: *Am J Hum Genet*. 2015 May

- 7;96(5):852. Lavault, Sophie [removed]; Arnulf, Isabelle [added]. PMID:25574827.
278. Holm A, Lin L, Faraco J, Mostafavi S, Battle A, Zhu X, Levinson DF, Han F, Gammeltoft S, Jennum P, **Mignot E**, Kornum BR. EIF3G is associated with narcolepsy across ethnicities. *Eur J Hum Genet.* 2015 Feb 11. doi: 10.1038/ejhg.2015.4. [Epub ahead of print] PMID: 25669430.
279. Kornum BR, Pizza F, Knudsen S, Plazzi G, Jennum P, **Mignot E**. Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. *Brain Behav Immun.* 2015 Mar 11. pii: S0889-1591(15)00075-6. doi: 10.1016/j.bbi.2015.03.004. [Epub ahead of print] PMID: 25771509.
280. Pizza F, Vandi S, Iloti M, Franceschini C, Liguori R, **Mignot E**, Plazzi G. Nocturnal Sleep Dynamics Identify Narcolepsy Type 1. *Sleep.* 2015 Mar 7. pii: sp-00505-14. [Epub ahead of print] PMID: 25845690
281. **Mignot EJ**. Erratum to: History of narcolepsy at Stanford University. *Immunol Res.* 2015 Jun;62(2):253. doi: 10.1007/s12026-15-8656-y. No abstract available. PMID: 25948476.
282. Christensen JA, Nikolic M, Warby SC, Koch H, Zoetmulder M, Frandsen R, Moghadam KK, Sorensen HB, **Mignot E**, Jennum PJ. Sleep spindle alterations in patients with Parkinson's disease. *Front Hum Neurosci.* 2015 May 1;9:233. doi: 10.3389/fnhum.2015.00233. eCollection 2015. PMID: 25983685.
283. Kornum BR, Rico T, Lin L, Huang YS, Arnulf I, Jennum P, **Mignot E**. Serum cytokine levels in Kleine-Levin syndrome. *Sleep Med.* 2015 Aug;16(8):961-5. doi: 10.1016/j.sleep.2015.02.540. Epub 2015 May 15. PMID: 26116465.
284. Kawai M, O'Hara R, Einen M, Lin L, **Mignot E**. Narcolepsy in African Americans. *Sleep.* 2015 Jun 22. pii: sp-00759-14. [Epub ahead of print] PMID: 26158891.
285. Jacob L, Leib R, Ollila HM, Bonvalet M, Adams CM, **Mignot E**. Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. *Brain Behav Immun.* 2015 Jul; 47: 44-57.
286. Gottlieb DJ, Hek K, Chen TH, Watson NF, Eiriksdottir G, Byrne EM, Cornelis M, Warby SC, Bandinelli S, Cherkas L, Evans DS, Grabe HJ, Lahti J, Li M, Lehtimäki T, Lumley T, Marcianti KD, Pérusse L, Psaty BM, Robbins J, Tranah GJ, Vink JM, Wilk JB, Stafford JM, Bellis C, Biffar R, Bouchard C, Cade B, Curhan GC, Eriksson JG, Ewert R, Ferrucci L, Fülöp T, Gehrman PR, Goodloe R, Harris TB, Heath AC, Hernandez D, Hofman A, Hottenga JJ, Hunter DJ, Jensen MK, Johnson AD, Kähönen M, Kao L, Kraft P, Larkin EK, Lauderdale DS, Luik AI, Medici M, Montgomery GW, Palotie A, Patel SR, Pistis G, Porcu E, Quaye L, Raitakari O, Redline S, Rimm EB, Rotter JI, Smith AV, Spector TD, Teumer A, Uitterlinden AG, Vohl MC, Widen E, Willemsen G, Young T, Zhang X, Liu Y, Blangero J, Boomsma DI, Gudnason V, Hu F, Mangino M, Martin NG, O'Connor GT, Stone KL, Tanaka T, Viikari J, Gharib SA, Punjabi NM, Räikkönen K, Völzke H, **Mignot E**, Tiemeier H. Novel loci associated with usual sleep duration: the CHARGE Consortium Genome-Wide Association Study. *Mol Psychiatry.* 2015 Oct;20(10):1232-9. doi: 10.1038/mp.2014.133. PMID: 25469926.

287. Li J, Moore H 4th, Lin L, Young T, Finn L, Peppard PE, **Mignot E**. Association of low ferritin with PLM in the Wisconsin Sleep Cohort. *Sleep Med*. 2015 Nov;16(11):1413-8. doi: 10.1016/j.sleep.2015.05.015. PMID: 26498245.
288. Christensen JA, Munk EG, Peppard PE, Young T, **Mignot E**, Sorensen HB, Jennum P. The diagnostic value of power spectra analysis of the sleep electroencephalography in narcoleptic patients. *Sleep Med*. 2015 Dec;16(12):1516-27. doi: 10.1016/j.sleep.2015.09.005. Epub 2015 Sep 15.
289. Christensen JA, Carrillo O, Leary EB, Peppard PE, Young T, Sorensen HB, Jennum P, **Mignot E**. Sleep-stage transitions during polysomnographic recordings as diagnostic features of type 1 narcolepsy. *Sleep Med*. 2015 Dec;16(12):1558-66. doi: 10.1016/j.sleep.2015.06.007. Epub 2015 Jul 7.
290. Plante DT, Finn LA, Hagen EW, **Mignot E**, Peppard PE. Subjective and Objective Measures of Hypersomnolence Demonstrate Divergent Associations with Depression among Participants in the Wisconsin Sleep Cohort Study. *J Clin Sleep Med*. 2016 Apr 15;12(4):571-8. doi: 10.5664/jcsm.5694. PMID: 26888592.
291. Gavrilov YV, Ellison BA, Yamamoto M, Reddy H, Haybaeck J, **Mignot E**, Baumann CR, Scammell TE, Valko PO. Disrupted Sleep in Narcolepsy: Exploring the Integrity of Galanin Neurons in the Ventrolateral Preoptic Area. *Sleep*. 2016 May 1;39(5):1059-62. doi: 10.5665/sleep.5754. PMID: 26951397
292. Nguyen QT, Groos E, Leclair-Visonneau L, Monaca-Charley C, Rico T, Farber N, **Mignot E**, Arnulf I. Familial Kleine-Levin Syndrome: A Specific Entity? *Sleep*. 2016 Aug 1;39(8):1535-42. doi: 10.5665/sleep.6014. PMID: 27253765.
293. Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, **Mignot E**. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. *Int J Obes (Lond)*. 2016 Aug;40(8):1310-9. doi: 10.1038/ijo.2016.52. PMID: 27005405.
294. Plante DT, Finn LA, Hagen EW, **Mignot E**, Peppard PE. Longitudinal associations of hypersomnolence and depression in the Wisconsin Sleep Cohort Study. *J Affect Disord*. 2016 Oct 3;207:197-202. doi: 10.1016/j.jad.2016.08.039. PMID: 27723544.
295. McConnell MV, Shcherbina A, Pavlovic A, Homburger JR, Goldfeder RL, Waggot D, Cho MK, Rosenberger ME, Haskell WL, Myers J, Champagne MA, **Mignot E**, Landray M, Tarassenko L, Harrington RA, Yeung AC, Ashley EA. Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts Cardiovascular Health Study. *JAMA Cardiol*. 2017 Jan 1;2(1):67-76. doi: 10.1001/jamacardio.2016.4395. PMID: 27973671.
296. Goldberg S, Ollila HM, Lin L, Sharifi H, Rico T, Andlauer O, Aran A, Bloomrosen E, Faraco J, Fang H, **Mignot E**. Analysis of Hypoxic and Hypercapnic Ventilatory Response in Healthy Volunteers. *PLoS One*. 2017 Jan 3;12(1):e0168930. doi: 10.1371/journal.pone.0168930. eCollection 2017. PubMed PMID: 28045995; PMCID: PMC5207520.
297. Olsen AV, Stephansen J, Leary E, Peppard PE, Sheungshul H, Jennum PJ, Sorensen H, **Mignot E**. Diagnostic value of sleep stage dissociation as visualized on a 2-dimensional sleep state space in human narcolepsy. *J Neurosci Methods*. 2017 Apr 15;282: 9-19. doi: 10.1016/j.jneumeth.2017.02.004. PMID: 28219726.

298. Ju YS, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, **Mignot E**, Zempel JM, Claassen JAHR, Holtzman DM. Slow wave sleep disruption increases cerebrospinal fluid amyloid- β levels. *Brain*. 2017 Aug 1;140(8):2104-2111. doi: 10.1093/brain/awx148. PubMed PMID: 28899014.
299. Koch H, Schneider LD, Finn LA, Leary EB, Peppard PE, Hagen E, Sorensen HBD, Jennum P, **Mignot E**. Breathing Disturbances Without Hypoxia Are Associated With Objective Sleepiness in Sleep Apnea. *Sleep*. 2017 Nov 1;40(11). doi: 10.1093/sleep/zsx152. PubMed PMID: 29029253.
300. Ruoff C, Pizza F, Trotti LM, Sonka K, Vandi S, Cheung J, Pinto S, Einen M, Simakajornboon N, Han F, Peppard P, Nevsimalova S, Plazzi G, Rye D, **Mignot E**. The MSLT is Repeatable in Narcolepsy Type 1 But Not Narcolepsy Type 2: A Retrospective Patient Study. *J Clin Sleep Med*. 2018 Jan 15;14(1):65-74. doi: 10.5664/jcsm.6882. PMID: 29198301.
301. Luo G, Lin L, Jacob L, Bonvalet M, Ambati A, Plazzi G, Pizza F, Leib R, Adams CM, Partinen M, **Mignot EJ**. Absence of anti-hypocretin receptor 2 autoantibodies in post pandemrix narcolepsy cases. *PLoS One*. 2017 Dec 8;12(12):e0187305. doi: 10.1371/journal.pone.0187305. eCollection 2017. Erratum in: *PLoS One*. 2019 Mar 28;14(3):e0214340. PMID: 29220370.
302. Hillary RP, Ollila HM, Lin L, Desestret V, Rogemond V, Picard G, Small M, Arnulf I, Dauvilliers Y, Honnorat J, **Mignot E**. Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies. *J Neuroimmunol*. 2018 Feb 15;315:28-32. doi: 10.1016/j.jneuroim.2017.12.012. Epub 2017 Dec 18. PMID: 29306402.
303. Olsen M, Schneider LD, Cheung J, Peppard PE, Jennum PJ, **Mignot E**, Sorensen HBD. Automatic, electrocardiographic-based detection of autonomic arousals and their association with cortical arousals, leg movements, and respiratory events in sleep. *Sleep*. 2018 Mar 1;41(3). doi: 10.1093/sleep/zsy006. PMID: 29329416.
304. Belbezier A, Joubert B, Montero-Martin G, Fernandez-Vina M, Fabien N, Rogemond V, **Mignot E**, Honnorat J. Multiplex family with GAD65-Abs neurologic syndromes. *Neurol Neuroimmunol Neuroinflamm*. 2017 Dec 5;5(1):e416. doi: 10.1212/NXI.0000000000000416. eCollection 2018 Jan. PMID: 29379821.
305. Cheung J, Ruoff C, Moore H, Hagerman KA, Perez J, Sakamuri S, Warby SC, **Mignot E**, Day J, Sampson J. Increased EEG Theta Spectral Power in Sleep in Myotonic Dystrophy Type 1. *J Clin Sleep Med*. 2018 Feb 15;14(2):229-235. doi: 10.5664/jcsm.6940. PMID: 29394960.
306. Moresco M, Lecciso M, Ocadlikova D, Filardi M, Melzi S, Kornum BR, Antelmi E, Pizza F, **Mignot E**, Curti A, Plazzi G. Flow cytometry analysis of T-cell subsets in cerebrospinal fluid of narcolepsy type 1 patients with long-lasting disease. *Sleep Med*. 2018 Apr;44:53-60. doi: 10.1016/j.sleep.2017.11.1150. Epub 2018 Jan 3. PMID: 29530370.
307. Olesen AN, Cesari M, Christensen JAE, Sorensen HBD, **Mignot E**, Jennum P. A comparative study of methods for automatic detection of rapid eye movement abnormal muscular activity in narcolepsy. *Sleep Med*. 2018 Apr;44:97-105. doi: 10.1016/j.sleep.2017.11.1141. Epub 2017 Dec 21. PMID: 29530376.

308. Wang W, Ollila HM, Whitemore AS, Demehri S, Ioannidis NM, Jorgenson E, **Mignot E**, Asgari MM. Genetic variants in the HLA class II region associated with risk of cutaneous squamous cell carcinoma. *Cancer Immunol Immunother.* 2018 Jul;67(7):1123-1133. doi: 10.1007/s00262-018-2168-2. Epub 2018 May 12. PMID: 29754218.
309. Plazzi G, Ruoff C, Lecendreux M, Dauvilliers Y, Rosen CL, Black J, Parvataneni R, Guinta D, Wang YG, **Mignot E**. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. *Lancet Child Adolesc Health.* 2018 Jul;2(7):483-494. doi: 10.1016/S2352-4642(18)30133-0. Epub 2018 May 21. PMID: 30169321.
310. Cheung J, Zeitzer JM, Lu H, **Mignot E**. Validation of minute-to-minute scoring for sleep and wake periods in a consumer wearable device compared to an actigraphy device. *Sleep Sci Pract.* 2018;2(1):11.
311. Leary EB, Moore HE 4th, Schneider LD, Finn LA, Peppard PE, **Mignot E**. Periodic limb movements in sleep: Prevalence and associated sleepiness in the Wisconsin Sleep Cohort. *Clin Neurophysiol.* 2018 Nov;129(11):2306-2314. doi: 10.1016/j.clinph.2018.08.022. Epub 2018 Sep 6. PMID: 30243181.
312. Olesen AN, Jennum P, Peppard P, Mignot E, Sorensen HBD. Deep residual networks for automatic sleep stage classification of raw polysomnographic waveforms. *Conf Proc IEEE Eng Med Biol Soc.* 2018 Jul;2018:1-4. doi: 10.1109/EMBC.2018.8513080. PMID: 30440296.
313. Stephansen JB, Olesen AN, Olsen M, Ambati A, Leary EB, Moore HE, Carrillo O, Lin L, Han F, Yan H, Sun YL, Dauvilliers Y, Scholz S, Barateau L, Hogl B, Stefani A, Hong SC, Kim TW, Pizza F, Plazzi G, Vandi S, Antelmi E, Perrin D, Kuna ST, Schweitzer PK, Kushida C, Peppard PE, Sorensen HBD, Jennum P, **Mignot E**. Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy. *Nat Commun.* 2018 Dec 6;9(1):5229. doi: 10.1038/s41467-018-07229-3. PMID: 30523329.
314. Luo G, Ambati A, Lin L, Bonvalet M, Partinen M, Ji X, Maecker HT, **Mignot EJ**. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. *Proc Natl Acad Sci U S A.* 2018 Dec 26;115(52):E12323-E12332. doi: 10.1073/pnas.1818150116. Epub 2018 Dec 12. PMID: 30541895.
315. Sakai N, Matsumura M, Lin L, **Mignot E**, Nishino S. HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy. *Sci Rep.* 2019 Jan 24;9(1):477. doi: 10.1038/s41598-018-36942-8. PMID: 30679597.
316. Hanif U, Schneider LD, Trap L, Leary EB, Moore H, Guilleminault C, Jennum P, Sorensen HBD, **Mignot EJM**. Non-invasive machine learning estimation of effort differentiates sleep-disordered breathing pathology. *Physiol Meas.* 2019 Feb 26;40(2):025008. doi: 10.1088/1361-6579/ab0559. PMID: 30736016.
317. Chambon S, Thorey V, Arnal PJ, **Mignot E**, Gramfort A. DOSED: A deep learning approach to detect multiple sleep micro-events in EEG signal. *J Neurosci Methods.* 2019 Jun 1;321:64-78. doi: 10.1016/j.jneumeth.2019.03.017. Epub 2019 Apr 1. PMID: 30946878.

318. Garrett-Bakelman FE, Darshi M, Green SJ, Gur RC, Lin L, Macias BR, McKenna MJ, Meydan C, Mishra T, Nasrini J, Piening BD, Rizzardi LF, Sharma K, Siamwala JH, Taylor L, Vitaterna MH, Afkarian M, Afshinnekoo E, Ahadi S, Ambati A, Arya M, Bezdán D, Callahan CM, Chen S, Choi AMK, Chlipala GE, Contrepois K, Covington M, Crucian BE, De Vivo I, Dinges DF, Ebert DJ, Feinberg JL, Gandara JA, George KA, Goutsias J, Grills GS, Hargens AR, Heer M, Hillary RP, Hoofnagle AN, Hook VYH, Jenkinson G, Jiang P, Keshavarzian A, Laurie SS, Lee-McMullen B, Lumpkins SB, MacKay M, Maienschein-Cline MG, Melnick AM, Moore TM, Nakahira K, Patel HH, Pietrzyk R, Rao V, Saito R, Salins DN, Schilling JM, Sears DD, Sheridan CK, Stenger MB, Tryggvadottir R, Urban AE, Vaisar T, Van Espen B, Zhang J, Ziegler MG, Zwart SR, Charles JB, Kundrot CE, Scott GBI, Bailey SM, Basner M, Feinberg AP, Lee SMC, Mason CE, **Mignot E**, Rana BK, Smith SM, Snyder MP, Turek FW. The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight. *Science*. 2019 Apr 12;364(6436). pii: eaau8650. doi: 10.1126/science.aau8650. PMID: 30975860.
319. Hershman SG, Bot BM, Shcherbina A, Doerr M, Moayedi Y, Pavlovic A, Waggott D, Cho MK, Rosenberger ME, Haskell WL, Myers J, Champagne MA, **Mignot E**, Salvi D, Landray M, Tarassenko L, Harrington RA, Yeung AC, McConnell MV, Ashley EA. Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study. *Sci Data*. 2019 Apr 11;6(1):24. doi: 10.1038/s41597-019-0016-7. PMID: 30975992.
320. Pouget JG; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Han B, Wu Y, **Mignot E**, Ollila HM, Barker J, Spain S, Dand N, Trembath R, Martin J, Mayes MD, Bossini-Castillo L, López-Isac E, Jin Y, Santorico SA, Spritz RA, Hakonarson H, Polychronakos C, Raychaudhuri S, Knight J. Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. *Hum Mol Genet*. 2019 Jun 18. pii: ddz145. doi: 10.1093/hmg/ddz145. PMID: 31211845.
321. Kim SJ, Kim S, Jeon S, Leary EB, Barwick F, **Mignot E**. Factors associated with fatigue in patients with insomnia. *J Psychiatr Res*. 2019 Jun 28;117:24-30. doi: 10.1016/j.jpsychires.2019.06.021. PMID: 31272015
322. Vandi S, Rodolfi S, Pizza F, Moresco M, Antelmi E, Ferri R, **Mignot E**, Plazzi G, Silvani A. Cardiovascular autonomic dysfunction, altered sleep architecture, and muscle overactivity during nocturnal sleep in pediatric patients with narcolepsy type 1. *Sleep*. 2019 Jul 29. pii: zsz169. doi: 10.1093/sleep/zsz169. PMID: 31353416.

Editorials, Reviews, Commentaries:

1. Elghozi JL, Laude D, Rey F, Ledard F, **Mignot E**, Duparat P, Meyer P (1985). Le 5-HIAA urinaire: signification et application aux antimigraineux (in French). Dans: "Les antimigraineux," *Actualites de Pharmacologie Clinique de l'Hopital Necker-Enfants Malades*, (eds.) P Meyer, H Albin, P Jaillon et F Lhoste, Masson.
2. **Mignot E**, De The H, Cloix JF, Meyer P (1985). Nouveaux facteurs humoraux mis en jeu dans la physiopathologie de l'hypertension (in French). *Coeur* 2000 8:355-358.

3. **Mignot E**, Garcia A (1986). Serotonine et dépression (in French). *Neuropsychiatrie*, 3:3-4.
4. Fajardo AG, **Mignot E** (1987). Implicaciones del sistema serotoninergico en la depresion (in Spanish). *Folia Neuropsychiatrica del Sur Y Este De Espan*, XXII(1), April.
5. Nishino S, **Mignot E**, Kuroda K, Sakai T, Dement WC. (1990): Involvement of central noradrenergic and cholinergic mechanisms in control of cataplexy in canine narcolepsy (in Japanese). *Shinkei Kenkyu no Shinpo (Advances in Neurological Sciences)*, 34: 461-473.
6. **Mignot E**, Dement WC (1992). Canine narcolepsy: a model of the human disorder. *Neurosciences Facts* (FIDIA research foundation), 3(3): 1.
7. **Mignot E**, Dement WC (1993). La Narcolepsie. *Le bulletin du FRM*, numéro spécial de novembre 1993, publication médicale scientifique, fonds de recherche medicale-Générale de Santé Cliniques, p. 2-3.
8. **Mignot E**, Edgar D, Prosser R, Dement WC (1993). Nouveaux concepts pour le developement d'hypnotiques. *Le bulletin du FRM*, numéro spécial de mars, publication médicale scientifique, fonds de recherche medicale-Générale de Santé Cliniques, p.4-5.
9. **Mignot E**, Dement WC (1993). Narcolepsy in animals and man. Editorial, *Equine Vet. J.*, 25(6): 476-477.
10. **Mignot E** (1994). Les gènes du sommeil. *Science et Vie Hors serie*, numéro hors serie de Décembre 1993" le sommeil", Groupe Excelcior Publications SA, Paris, 185: 98-109.
11. Nishino S, Reid M, Dement WC, **Mignot E** (1994). Neuropharmacology and neurochemistry of canine narcolepsy. *Sleep*, 17(8): S84-S92.
12. **Mignot E** (1994). Narcolepsy: A disorder of REM sleep that involves the immune system. *Sleep Medicine Revue*, 2(2): 1-2.
13. **Mignot E**, Tafti M (1994). La vie au rythme de la lumiere. *Science et Vie Hors serie*, numéro hors serie de Mars 1994 "la lumière", Groupe Excelcior publications SA, Paris, 186: 152-156 .
14. **Mignot E** (1994). Modafinil: A new stimulant for narcoleptic patients. *The Network*, narcolepsy net work publication. 7(1): 1-3, Spring.
15. **Mignot E**, Tafti M, Dement WC, Grumet FC (1995). Narcolepsy and Immunity. *Adv. Neuroimmunol.*, 5(1): 23-37
16. **Mignot E** (1995). Molecular Biology and Sleep Research: A future for Gene Mappers. *World Federation of Sleep research Societies Newsletter*, 4(1): 21-22.
17. **Mignot E** (1995). Génétique de la narcolepsie. *Journal de Pharmacologie*. Numero spécial consacré au Modafinil (Modiodal) dans les pathologies de l'éveil, 9(8 suppl): 15-17.
18. **Mignot E**, Nishino S, Dement WC (1995). Narcolepsie, sommeil et immunité. *Neuropsychiatrie*, 10(8): 392-399.
19. **Mignot E**. Narcolepsy (1995). Basic Research Update. *Report for the National Center For Sleep Disorders Research in the National Institutes of Health (NIH)*, June.
20. **Mignot E** (1996). Nature, Nurture and Narcolepsy. *Perspective from the Narcolepsy Institute*, vol 1(2): p. 1-6.
21. Nishino S, **Mignot E** (1996). Pharmacological aspects of human and canine narcolepsy. *Prog. Neurobiol.*, 52(1): 27-78.

22. **Mignot E** (1996). Perspectives in narcolepsy research and therapy. *Curr. Opin. Pulm. Med.*, 2(6): 482-487.
23. **Mignot E** (1998). An update on genetic studies in narcolepsy. *Sleep Alert*, 3(3):1.
24. **Mignot E** (1998). Searching for narcolepsy genes. *The Network*, 54.
25. **Mignot E** (1998). Genetic and familial aspects of narcolepsy. In: *Current Issues in the Diagnosis and Management of Narcolepsy. Neurology*, 50(suppl 1): S16-22.
26. Guilleminault C, Heinzer R, **Mignot E**, Black J (1998). Investigations into the neurological basis of narcolepsy. In: *Current Issues in the Diagnosis and Management of Narcolepsy, Neurology*, 50(suppl 1): S8-15.
27. **Mignot E** (1998). Genetics of narcolepsy and other sleep disorders. *Am. J. Hum. Genet.*, 60: 1289-1302.
28. Nishino S, **Mignot E** (1998). Neurobiology of narcolepsy. *The Neuroscientist*, 4(2): 133-143.
29. Kadotani H, Faraco J, **Mignot E** (1998). Genetic studies in the sleep disorder narcolepsy. *Genome Res.*, 8(5): 427-434.
30. Faraco J, Lin X, Li R, Hinton L, Lin L, **Mignot E** (1999). Genetic studies in narcolepsy, a disorder affecting REM sleep. *J. Hered.*, 90(1): 129-132.
31. Faraco J, **Mignot E** (1999). Genetic studies in the sleep disorder narcolepsy. *Sleep Research Society (SRS) Bulletin*, 5(1): 8-14.
32. Nishino S, **Mignot E** (1999). Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations. *Clin. Pharmacokinet.*, 37(4):305-330.
33. **Mignot E** (2000). Decoder la narcolepsie. *La Recherche Hors Serie No 3*: 78-81.
34. Hungs M, **Mignot E** (2000). Hypocretin deficiency causes narcolepsy in animals and humans. *Somnology*, 4: 111-116.
35. **Mignot E** (2000). Perspectives in narcolepsy and hypocretin (orexin) research. *Sleep Med.*, 1(2): 87-90.
36. **Mignot E** (2000). Research Breakthrough: A lack of hypocretin (orexin) causes Narcolepsy. *The Network (narcolepsy network)*, 13(2): 1-2, Spring.
37. Nishino S, Okura M, **Mignot E** (2000). Narcolepsy: Genetic predisposition and neuropharmacological mechanisms. *Sleep Medicine Review*, 4 (1): 57-99.
38. **Mignot E** (2001). A hundred years of narcolepsy research. *Arch. Ital. Biol.*, 139(3): 207-20.
39. **Mignot E**, Thorsby E (2001). HLA association, hypocretin mutations and narcolepsy. *N. Engl. J. Med.*, 344(9): 692.
40. Hungs M, **Mignot E** (2001). Hypocretin/Orexin, sleep and narcolepsy. *Bioessays* 23: 1-12.
41. Lin L, Hungs M, **Mignot E** (2001). Narcolepsy and the HLA region. *J. Neuroimmunol.*, 117(1-2): 9-20.
42. Nevsimalova S, Vankova J, Sonka K, Faraco J, Rogers W, Overeem S, **Mignot E** (2000). Deficit hypocretinu (orexinu) U narkolepsie-kataplexie. *Sbornik lekarsky*, 101(4): 381-386.
43. **Mignot E** (2001). Hypocrétine (orexine) et narcolepsie: Dormir ou diner? *Lettres des Neurosciences*, 20: 15-16.
44. **Mignot E**, Young T, Murphy G (2001). Relationship between apolipoprotine E ε4 and sleep-disordered breathing at different ages. *JAMA*, 286(12): 1448-1449.

45. **Mignot E** (2001). A commentary on the neurobiology of the hypocretin/orexin system. *Neuropsychopharmacology*, 25: S5-S13.
46. **Mignot E** (2002). New directions for narcolepsy research. *The Network -A* publication of the Narcolepsy Network. Spring 2002.
47. Nishino S, **Mignot E** (2002). A commentary on: Plasma orexin-A is lower in patients with narcolepsy. *Sleep Med.*, 3(4): 377-378.
48. Taheri S, **Mignot E** (2002). The genetics of sleep disorders. *Lancet Neurol.* 1(4): 242-250.
49. **Mignot E**, Taheri S, Nishino S (2002). Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. *Nat. Neurosci.*, Suppl: 1071-1075.
50. Taheri S, Zeitzer JM, **Mignot E** (2002). The role of hypocretin (orexin) in sleep regulation and narcolepsy. *Annu. Rev. Neurosci.*, 25: 283-313.
51. Thorpy MJ, **Mignot E** (2002). How to improve outcomes when managing narcolepsy. *Practical Neurology*, 1(6): 28-31.
52. Chabas D, Taheri S, Renier C, **Mignot E** (2003). The genetics of narcolepsy. *Annu. Rev. Genomics Hum. Genet.*, 4: 459-483.
53. **Mignot E**, Chen W, Black J (2003). On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy. *Sleep*, 26(6): 646-649.
54. **Mignot E** (2003). President's Message. *Sleep Research Society (SRS) Bulletin* 9(1): 4-5.
55. **Mignot E** (2003). President's Message: The NIH Roadmap. *Sleep Research Society (SRS) Bulletin*, Winter issue, 9(2): 4-5.
56. Fromherz S, **Mignot E** (2004). Narcolepsy Research: past, present, and future Perspectives. *Arch. Ital. Biol.*, 142(4): 479-486.
57. **Mignot E** (2004). What can genetics contribute to the management of sleep disorders? *INSOM*, issue 3 (Suppl 1).
58. **Mignot E** (2004). Sleep, sleep disorders and hypocretin (orexin). *Sleep Med.* Suppl 1:S2-8.
59. Bourgin P, **Mignot E** (2004). Review: Hypocrétines, nutrition, sommeil normal et pathologique. *Médecine du Sommeil*, Septembre, 1: 17-23.
60. Arnulf I, **Mignot E** (2004). Sodium oxybate for excessive daytime sleepiness in narcolepsy-cataplexy. *Sleep* 27(7): 1242-1243.
61. **Mignot E**, Nishino S (2005). Emerging therapies in narcolepsy-cataplexy. *Sleep*, 28(6):754-763.
62. Mahmood M, **Mignot E** (2005). Delve deeper into sleep disorders. *Practical Neurology*, 4(6): 48-57.
63. Shepard Jr JW, Buysse DJ, Chesson Jr AL, Dement WC, Goldberg R, Guilleminault C, Harris CD, Iber C, **Mignot E**, Mitler MM, Moore KE, Phillips BA, Quan SF, Rosenberg RS, Roth T, Schmidt HS, Silber MH, Walsh JK, White DP, (2005). History of the development of sleep medicine in the United States. *J. Clin. Sleep Med.* 1(1): 61-82.
64. Giovanni C, Skarulis M, **Mignot E** (2005). A Link Between Short Sleep and Obesity: Building the Evidence for Causation. *Sleep*, 28(10): 1217-1220.
65. Arnulf I, Zeitzer J, File J, Farber N, **Mignot E** (2005). Kleine-Levin Syndrome: a Systematic Review of 186 Cases in the Literature. *Brain*, 128(Pt 12):2763-76.
66. Zeitzer, JM, Nishino S, **Mignot E** (2006). The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. *Trends Pharmacol. Sci. (TIPS)*, 27(7):368-74.

67. Schenck C, Bassetti C, Arnulf I, **Mignot E** (2006) English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gelineau in the late 19th century, with commentary, *J. Clin. Sleep Med.*, 3(3):301-11.
68. Dauvilliers Y, Arnulf I, **Mignot E** (2007). Narcolepsy with cataplexy. *Lancet*. 369(9560):499-511.
69. **Mignot E**, Takahashi JS (2007). A circadian sleep disorder reveals a complex clock. *Cell*, 128(1):22-3.
70. **Mignot E**, (2007) A step forward for restless leg syndrome. *Nat Genet*. Aug;29(8):938-9.
71. Hirst J, **Mignot E**, Stein MT (2007). Episodic Hypersomnia and Unusual Behaviors in a 14-Year Old Adolescent. *J. Dev. Behav. Pediatr.* 2007 Dec;28(6):475-477.
72. **Mignot E**, (2008) Excessive daytime sleepiness: population and etiology versus nosology. *Sleep Med. Rev.* April;12(12):87-92.
74. **Mignot E**, Mourrain P, Zeitzer J, Yokogawa T (2008). Indeed it does. Response to Rial R, Nicolau M, Gamundi A, Akaâr M, Aparicio S, Garau C, Tejada S, Gené L, Moranta D, Esteban D, Zebrafish: Does It Really Sleep? *Plos Biol.* <http://biology.plosjournals.org/perlserv/?request=read-response&doi=10.1371/journal.pbio.0050277>.
75. **Mignot E** (2008). Why we sleep: Temporal organization of recovery. *Plos Biol*; 6(4):e106..<http://biology.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pbio.0060106>
76. Bourgoin P, Zeitzer J, **Mignot E** (2008). Hypocretin in sleep and neurological disorders. *Lancet Neurol.* 7(7):649-62. Review. Erratum in: *Lancet Neurol.* 7(9):771.
77. Capasso R, **Mignot E** (2008) Diagnosis and Management of Common Sleep Disorders: An overview for the Psychiatrist, *European Psychiatric Review*, 2008, 1-8.
78. **Mignot E** (2009). New DNA technique Furthers Narcolepsy Research . The Network, Winter 2009, 1-2, 12-13.
79. **Mignot E** (2009) . A new gene for narcolepsy implicates the immune system in the cause of narcolepsy. The Network, Spring 2009, 2-4.
78. Aran A, Hirshber B. Arnulf I, **Mignot E** (2009). Periodic Hypersomnia: Kleine-Levin Syndrome subtype. *Up to date*, in press.
79. Aran A, **Mignot E** (2009). The immune system, the brain and narcolepsy. *Future Neurology*, in press.
80. **Mignot E** (2009). Narcolepsy as a model for brain autoimmune diseases. *Frontiers in Neuroscience*, in press.
81. **Mignot E**, Huguenard J (2009). Resting our Cortices while Going DOWN to sleep. *Neuron* (Commentary), 63(6):719-21.
82. **Mignot E** (2009). In memoriam of Dr. Yutaka Honda (1929-2009), a pioneer in sleep medicine and narcolepsy research. *Sleep*, in press.
83. Lammers GJ, Bassetti C, Billiard M, Black J, Broughton R, Dauvilliers Y, Ferini Strambi L, Garcia-Borreguero D, Goswami M, Högl B, Iranzo A, Jennum P, Khatami R, Lecendreux M, Mayer G, **Mignot E**, Montplaisir J, Nevsimalova S, Peraïta-Adrados R, Plazzi G, Scammell T, Silber M, Sonka K, Tafti M, Thorpy M (2010). Sodium oxybate is an effective and safe treatment for narcolepsy. *Sleep Med.* 2010, 11(1):105-6; author reply 106-8.

84. Reynolds CF 3rd, Redline S; The DSM-V sleep-wake disorders nosology (**Mignot E**): an update and an invitation to the sleep community. DSM-V Sleep-Wake Disorders Workgroup and Advisors. *Sleep*; 33(1):10-1
85. Reynolds CF 3rd, Redline S, DSM-V Sleep-Wake Disorders Workgroup and Advisors (**Mignot E**) (2010).The DSM-v sleep-wake disorders nosology: an update and an invitation to the sleep community. *J Clin Sleep Med* 6 (1):9-10
86. Taheri S, **Mignot E**. Sleep well and stay slim: dream or reality? *Ann Intern Med*. 2010;153(7):475-6.
87. Nishino S, **Mignot E**. Narcolepsy and cataplexy. *Handb Clin Neurol*. 2011;99:783-814.
88. Kornum BR, Faraco J, **Mignot E**. Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. *Curr Opin Neurobiol*. 2011 Sep 30. [Epub ahead of print]
89. Sehgal A, **Mignot E**. Genetics of sleep and sleep disorders. *Cell*. 2011 Jul 22;146(2):194-207. Review.
90. **Mignot E**, Dauvilliers Y, Montplaisir J. Comment on the Letter to the Editor by Dr. Marcus on the association between narcolepsy and H1N1 exposure *Sleep* 2011, Vol. 34, 689-690.
91. **Mignot E**. A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes. *Neurotherapeutics, Neurotherapeutics*. 2012 Oct;9(4):739-52.
92. **Mignot E**. Physiology. The perfect hypnotic? *Science*. 2013 Apr 5;340(6128):36-8.. No abstract available. Erratum in: *Science*. 2013 May 31;340(6136):1042.
93. Singh AK, Mahlios J, **Mignot E**. Genetic association, seasonal infections and autoimmune basis of narcolepsy. *J Autoimmun*. 2013 Jun;43:26-31.
94. Pelayo R, **Mignot E**. The treatment of sleep disorders. *Neurotherapeutics*. 2012 Oct;9(4):685-6.
95. Arnulf I, Rico TJ, **Mignot E**. Diagnosis, disease course, and management of patients with Kleine-Levin syndrome. *Lancet Neurol*. 2012 Oct;11(10):918-28.
96. Mahlios J, De la Herrán-Arita AK, **Mignot E**. The autoimmune basis of narcolepsy. *Curr Opin Neurobiol*. 2013 May 29. doi:pil: S0959-4388(13)00102-5.
97. Roth T, Dauvilliers Y, **Mignot E**, Montplaisir J, Paul J, Swick T, Zee P. Disrupted nighttime sleep in narcolepsy. *J Clin Sleep Med*. 2013 Sep 15;9(9):955-65. Review
98. Jacob L, **Mignot E**. Histoire de la narcolepsie de 1877 à 1980 émergence d'une nouvelle entité Clinique. *Hist Sci Med*. 2016 Jan-Mar;50(1):69-74. French. PubMed PMID: 27349127.
99. Schneider L, **Mignot E**. Diagnosis and Management of Narcolepsy. *Semin Neurol*. 2017 Aug;37(4):446-460. doi: 10.1055/s-0037-1605554. Epub 2017 Aug 24. PubMed PMID: 28837992.
100. Bonvalet M, Ollila HM, Ambati A, **Mignot E**. Autoimmunity in narcolepsy. *Curr Opin Pulm Med*. 2017 Nov;23(6):522-529. doi: 10.1097/MCP.0000000000000426. PubMed PMID: 28991006.

101. Hershner S, Dauvilliers Y, Chung F, Singh M, Wong J, Gali B, Kakkar R, **Mignot E**, Thorpy M, Auckley D. Knowledge Gaps in the Perioperative Management of Adults With Narcolepsy: A Call for Further Research. *Anesth Analg*. 2019 Jul;129(1):204-211. doi: 10.1213/ANE.0000000000004088. PMID: 30882519.
102. **Mignot E**, Ambati A, Luo G. Response to "H1N1 hemagglutinin-specific HLA-DQ6-restricted CD4+ T cells can be readily detected in narcolepsy type 1 patients and healthy controls". *J Neuroimmunol*. 2019 Aug 15;333:476959. doi: 10.1016/j.jneuroim.2019.04.019. Epub 2019 May 1. PMID: 31108400.
103. Edwards K, Hanquet G, Black S, **Mignot E**, Jankosky C, Shimabukuro T, Miller E, Nohynek H, Neels P. Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting. *Biologicals*. 2019 Jul;60:1-7. doi: 10.1016/j.biologicals.2019.05.005. Epub 2019 May 23. PMID: 31130313.

Book Chapters:

1. **Mignot E**, Nishino S, Dean R, Valtier, D, Guilleminault C, Dement WC (1989). Noradrenergic and cholinergic control of cataplexy: Evidence using a canine model of narcolepsy and therapeutic implications. In: *Narcolepsy 3rd International symposium, symposium proceedings*, (eds.) ICI Pharmac, ICI America Inc., p.37-54.
2. **Mignot E**, Guilleminault C (1989). Receptology in narcolepsy. In: *Neurology in Europe I*, (eds.) D Bartko, F Gerstenbrand and P Turcani, John Libbey et co Ltd, London, p.521-530.
3. **Mignot E**, Nishino S, Valtier D, Guilleminault C, Dement WC (1990). Rôle des systèmes cholinergiques et noradrénergiques centraux dans le contrôle de la narcolepsie, une maladie du sommeil paradoxal (in French). Dans: *"Etats de veille et de sommeil"*. Actualités Pharmacologiques de l'Hopital Necker Enfants Malades 7, (eds.) P. Meyer, JL Elghozi et A. Quera Salva, Masson, p.55-70.
4. **Mignot E**, Nishino S, Guilleminault C, Dement WC (1990). Neuropharmacology of canine narcolepsy. In: *Endogenous Sleep Factors*, (eds.) Kruger J, Inoue S, Bouma, Text, Wassenaar, p.203-215.
5. Fruhstorfer, B, **Mignot, E**, Nishino, S, Dement, WC, Guilleminault, C (1990). Health risk narcolepsy: alpha adrenoceptors involved in sleep and arousal mechanism In: *International Symposium: Sleep and Health Risk, Proceedings*. Philipps-Universitat, Marburg, p.29.
6. Nishino S, **Mignot E**, Fruhstorfer B, Kilduff T, Veno R, Hayaishi O, Dement WC (1990). Effects of intravenous administrations of prostaglandins on canine narcolepsy. In: *Endogenous Sleep Factors*, (eds.) Kruger J, Inoue S, Bouma, Text, Wassenaar, p.77-83.
7. **Mignot E**, Nishino S, Valtier D, Renaud A, Guilleminault C, Dement WC (1990). Pharmacological control of narcolepsy. In: *Sleep '90*, (eds.) Horne J, Pontenagel Press, Bochum, p.409-415.

8. Fruhstorfer B, **Mignot E**, Nishino S, Dement, WC, Guilleminault C (1991). Health risk narcolepsy: Evidence for involvement of alpha-adrenergic mechanisms. In: *Sleep and Health Risk*, (eds) Peter JH, Penzel T, Podszus T, Wichert PV, Springer-Verlag, Berlin Heidelberg p.146-153.
9. **Mignot E**, Guilleminault C, Dement WC, Grumet C (1992). Genetically determined animal models of narcolepsy, a disorder of REM sleep. In: *Genetically determined Animal Models of Neurobehavioral Dysfunction*, (eds.) Driscoll D, Birkhauser Boston Inc., Cambridge, p.90-110.
10. Dement WC, **Mignot E** (1992). Can narcolepsy be eradicated in this millennium. In: *Loss, Grief and Care*, Haworth Press, Kirwood, New York, 5: 193-203.
11. **Mignot E**, Edgar DM, Miller JD, Prosser RA, Van Gelder RN, Nishino S, Dement WC (1992). Strategies for the development of new treatments in sleep disorders medicine. In: *Target receptors for Anxiolytics and hypnotics: From Molecular pharmacology to Therapeutics. International Academy for Biomedical Drug Research*, Mendlewicz J, Racagni G (eds.), Karger AG, Basel, p.129-150.
12. **Mignot E**, Dement WC, Grumet FC (1992). Narcolepsy and immune related genes. In: *HLA 1991, Proceedings of the 11th International Histocompatibility Workshop and Conference*, Volume II, 6-13 November 1991, Yokohama, K Tsuji, M Aizawa, T Sasazuki (eds.), Oxford university Press, New York, p.554-557.
13. Kuwata S, Juji T, Sasaki T, Honda Y, Wong KH, Mervart HM, Haddad AP, Acton RT, Cross RA, Bing AJ, **Mignot E**, Grumet FC (1992). The first international collaborative study on narcolepsy. In: *HLA 1991, Proceedings of the 11th International Histocompatibility Workshop and Conference*, Volume I, 6-13 November 1991, Yokohama, K Tsuji, M Aizawa, T Sasazuki (eds), Oxford university Press, New York, p.730-734.
14. **Mignot E**, Guilleminault C, Grumet FC, Dement WC (1992). Is narcolepsy an autoimmune disease? In: *Proceedings of Third Milano International Symposium Sleep, Hormones and Immunological System*, Milano, Masson, September 18-19, p.29-38.
15. **Mignot E**, Guilleminault C (1993). Pharmacological control of narcolepsy and REM sleep. In: *Endocrine and nutritional control of basic biological functions*. Lehnert H, Murison R, Weiner H, Hellmammer D, Beyer J (eds.), Hogrefe & Huber Publishers, Seattle, Toronto, p.307-314.
16. **Mignot E**, Nishino S, Reid M, Dement WC (1993): How do stimulant and anticataplectic compounds work? In: *Proceedings of the Life of the Sleepy Person II Conference: New Perspectives on Disorders of Excessive Sleepiness*, Chicago, March 4-5.
17. Nishino S, **Mignot E**, Dement WC (1995). Sedative hypnotics. In: *Textbook of Psychopharmacology*, (eds.) Schatzberg and Nemeroff, Oxford University Press, p405-416.
18. Nishino S, **Mignot E**, Dement WC (1994). Sedative-hypnotics. In Schatzberg AF, Nemeroff CB (eds) *Textbook of Psychopharmacology*, American Psychiatric Press, Washington, DC, p. 405-416.
19. **Mignot E**, Tafti M, Dement WC (1994). Génétique moléculaire et sommeil. In: *Le sommeil normal et pathologique*, (eds.) M. Billiard, Masson, Paris, p.53-66.

20. Jin L, Macaubas C, Hallmayer J, Kimura A, **Mignot E** (1995). Tracking the evolutionary history of a microsatellite locus located in the HLA DQA1/DQB1 class II region: A phylogenetic approach. In: *Current Topics on Molecular Evolution*, (eds.) M. Nei and N. Takahata, Proceedings of the Bionational Workshop on Molecular Evolution, Japan, August 25-27 p. 79-87.
21. **Mignot E**, Nishino S, Dement WC (1995). Narcolepsy, A disorder of REM sleep that involves the immune system. In: *Proceeding of the First International Conference: Toward the cause of narcolepsy*, National Sleep Foundation, Lansdowne, Washington D.C., July 1995 p. 8-16.
22. **Mignot E** (1996). Genetic and familial aspects of narcolepsy. *Narcolepsy Seminar Syllabus, Meeting of the American Academy of Neurology*, San Francisco, CA, March.
23. **Mignot E**, Kimura A, Lattermann A, Grumet FC, Mayer G, Thorspy E, Hesla PE, Mueller-Eckardt G. HLA class II studies in non DRB1*1501 patients with narcolepsy-cataplexy. In: *HLA 1996, Proceedings of the 12th International Histocompatibility Workshop and Conference: Genetic Diversity of HLA: Functional and Medical Implications*, Volume I, 3-12 June 1996, St. Malo, France, (ed.), D. Charron, EDK Press, Paris, France, p.436-441.
24. Nishino S, **Mignot E**, Dement WC (1996). Sedative-hypnotics. In: *Textbook of Psychopharmacology*, revised, (eds.) A. Schatzberg, CB. Nemeroff, American Psychiatric Press, Washington DC, p. 487-502.
25. **Mignot E**, Nishino S (1996). Genetical and pathophysiological aspects of narcolepsy. In: *The 9th Takeda Science Foundation Symposium on Bioscience: Sleep and Sleep Disorders: From Molecule to Behavior*, 4-7 December 1996, p.325-340.
26. **Mignot E**, Macaubas C, Jin L, Hallmayer J, Kimura A, Grumet FC (1997). The natural history of a microsatellite located in the HLA DQ region. In: *HLA 1996, Proceedings of the 12th International Histocompatibility Workshop and Conference: Genetic Diversity of HLA Functional and Medical Implications*, Volume II, 3-12 June 1996, St. Malo, France, (ed.) D. Charron, ESK Press, Paris, France, p.121-124.
27. **Mignot E** (1998). La Narcolepsie. In: *Confrontations Psychiatriques, Sommeil et Psychiatrie*, Laboratoires Rhone-Poulenc Rorer, p. 81-106.
28. **Mignot E**, Nishino S (1998). Narcolepsy. In: *Handbook of Behavioral State Control: Cellular and Molecular Mechanisms*, (eds.) R. Lkydic and H.A., Baghdoyan, CRC Press, Inc., Boca Raton, FL, p. 129-141.
29. **Mignot E**, Tafti M (1998). Génétique moléculaire, rythmes circadiens et sommeil. In: *Le sommeil normal et pathologique*, 2nd edition, (eds.) M. Billiard, Masson, Paris, pp 66-85.
30. Kilduff T, **Mignot E** (1999). Molecular and genetic aspects of sleep. In: *Regulation of Sleep and Circadian Rhythms*, (eds.) F.W. Turek and P. Zee, Marcel Dekker, Inc., New York, p. 343-367.
31. **Mignot E** (1999). Human and animal genetics of sleep and its disorders. In: *Sleep Disorders Medicine: Basic Science, Technical Considerations and Clinical Aspects*, 2nd edit, (eds.) S. Chokroverty, Butterworth-Heinemann, New York, p. 317-330.
32. **Mignot E** (1999). AAN syllabus: narcolepsy research and therapy update. *American Academy Neurology*, Apr. 17-24.

33. O'Hara B, **Mignot E** (2000). Genetics of Sleep and Its Disorders. In: *Handbook of Genetic Influences on the Nervous System*, (eds) Donald Pfaff, CRC Press, Inc., Boca Raton, FL, p. 307-326.
34. **Mignot E** (2000). Pathophysiology of Narcolepsy. In: *Principles and Practice in Sleep Medicine*, 3rd edition, (eds) MH Kyger, T Roth, WC Dement, WB Sanders Company, Philadelphia, PA, p. 663-675.
35. Nishino S, Honda K, Fujiki N, Wurts S, Sakurai E, Kato M, Watanabe T, **Mignot E**, Yanai K (2000). CSF histamine levels in narcolepsy and hypersomnia. In: *Proceedings of the International Sendai Histamine Symposium*, Sendai, Japan, November 22-25. Elsevier Science.
36. Overeem S, **Mignot E**, van Dijk JG, Lammers GJ (2001). Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. *J. Clin. Neurophys.*, 18(2): 78-105.
37. **Mignot E**, Hungs M (2001). AAN syllabus: New Insights in Narcolepsy. *Syllabus, 53rd American Academy of Neurology Annual Meeting*, Philadelphia, PA, May 5-11.
38. **Mignot E**, Nishino S (2002). Pathophysiological and pharmacological aspects of the sleep disorder narcolepsy. In: *Neuropharmacology: The Fifth Generation of Progress*, An official publication of the ACNP (eds) KL Davis, D Charney, JT Coyle, C Nemeroff; DJ Kupfer section editor, Lippincott Williams & Wilkins, Baltimore, MD, 1907-1921.
39. Brooks SN, **Mignot E** (2002). Narcolepsy and Idiopathic Hypersomnia. In: *Sleep Medicine*, (eds) TL Lee-Chiong, Jr., MJ Sateia, MA Carskadon, Hanley & Belfus, Inc., Philadelphia, PA, p.193-202.
40. **Mignot E** (2003). Narcolepsy. In: *The Dana Guide to Brain Health and Disorders*, (eds) F Bloom, F Beal, D Kupfer, Free Press, New York, NY, p. 315-319.
41. Nishino S, **Mignot E**, Dement WC (2003). Sedative hypnotics. In: *Textbook of Psychopharmacology, 3rd Edition*, (eds.) Schatzberg and Nemeroff, Oxford University Press, p. 651-670.
42. **Mignot E** (2004). Narcolepsy. In: *The World Book Encyclopedia*, World book, 2004 edition, p. 19-22.
43. Nishino S, Taheri S, Blac J, Nofzinger E, **Mignot E** (2004). The Neurobiology of Sleep in Relation to Mental Illness, in *The Neurobiology of Mental Illness*, Second Edition, (eds) D Charney and EJ Nestler, Oxford University Press, San Francisco, CA, p. 1272-1283.
44. **Mignot E** (2004). Narcolepsy and its management in women. In: *Clinical Updates in Women's Health Care*, (eds) Hunt CE, Buysse DJ, Germain A, Hall M, Landis CA, Lee KA, **Mignot E**, Phillips B An American College of Obstetricians and Gynecologists publication, vol. III, issue 2, p. 69-75.
45. Nishino S, Mishima K, **Mignot E**, Dement WC (2004). Sedative-hypnotics. In: *Textbook of Psychopharmacology*, (eds) A Schatzberg, CB Nemeroff, American Psychiatric Press, Washington DC, p. 651-670.
46. **Mignot E**, Silber M, Billiard M, Chervin R, Honda Y, Lammers G, Nishino S, Scammell T, Bassetti C, Broughton R, Kanbayashi T, Guilleminault C (2005). Hypersomnia section: all disorders; normal variant section: short and long sleeper, In: *The International Classification of Sleep Disorders, Diagnostic and Coding Manual (ICSD-2), 2nd edition*, American Academy of Sleep Medicine, Chicago, IL, p.79-115 and p.197-203.

47. Nishino S, **Mignot E** (2005). Wake Promoting Medications: Basic Mechanisms and Pharmacology. In: *Principles and Practice in Sleep Medicine*, 4th edition, (eds) MH Kyger, T Roth, WC Dement, WB Sanders Company, Philadelphia, PA, p.468-483.
48. **Mignot E** (2005). Narcolepsy: Pharmacology, Pathophysiology and Genetics. In: *Principles and Practice in Sleep Medicine*, 4th edition, (eds) MH Kyger, T , Roth, WC Dement, WB Sanders Company, Philadelphia, PA, p. 761-779.
49. Zeitzer JM, **Mignot E** (2005). Sleep mechanisms: neurochemistry and CNS peptides. In: *The SRS Basics of Sleep Guide*. Sleep Research Society: Westchester IL, p. 67-71.
50. **Mignot E**, Lin L, Li H, Thomson G, Lathrop M, Thorsby E, Tokunaga K, Honda Y, Dauvilliers Y, Tafti M, Billiard M, Mayer G, Montplaisir J, Rouleau G, Temple H, Thorpy M, Martins B, Silva A, Vazquez M, Alaez C, Gorodezky C, Schoch G, Lo B, Grumet F (2006). HLA allele and microsatellite studies in narcolepsy. In: *Immunobiology of Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Congress* (Seattle, WA 2004), (eds) Hansen J, Dupont B, Volume I&II, IHWG Press, Fred Huchinston Cancer Research Center, Seattle, WA, USA p. 817-823.
51. Thorsby E, Caillat-Zucman S, Dorman J, Eliaou JF, Lathrop M, Li H, Lie BA, Mazzilli MC, **Mignot E**, Nelson JL, Pugliese A, Reveille J, Thomson G, Toubert A (2006). *Additional disease predisposing genes in the HLA complex. A summary of the 13. IHWS Disease Component Study*, In: *Immunobiology of Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Congress* (Seattle, WA 2004), (eds) Hansen J, Dupont B, Volume I&II, IHWG Press, Fred Huchinston Cancer Research Center, Seattle, WA, USA p. 823-830.
52. Thomson G, Li H, Dorman JS, Lie BA, **Mignot E**, Steenkiste A, Akey JM, McWeeney S, Single R (2006). *Statistical approaches for analyses of HLA-associated and other complex diseases*. In: *Immunobiology of Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Congress* (Seattle, WA 2004), (eds) Hansen J, Dupont B, Volume I&II, IHWG Press, Fred Huchinston Cancer Research Center, Seattle, WA, USA pp782-787.
53. Bourgin P, Zeitzer JM, **Mignot E** (2005). Hypocretin deficiency in human narcolepsy: mutation screening neuropathology and CSF hypocretin-1 level. In: *Contemporary Clinical Neuroscience: The Orexin /Hypocretin System: Physiology and Pathophysiology*, (eds) Nishino S, Sakurai T, Humana: Totowa, NJ, p. 269-286.
54. Fromherz S, **Mignot E** (2005). Overview of human narcolepsy. In: *Contemporary Clinical Neuroscience: The Orexin /Hypocretin System: Physiology and Pathophysiology*, (eds.) Nishino S, Sakurai T, Humana Press Inc. Totowa NJ, p. 221-231.
55. Taheri S, Paterno J, Lin L, **Mignot E** (2005). Narcolepsy and Autoimmunity. In: *Contemporary Clinical Neuroscience: The Orexin /Hypocretin System: Physiology and Pathophysiology*, (eds.) Nishino S, Sakurai T, Humana Press Inc. Totowa NJ, p. 341-346.

55. Chen W, Zeitzer JM, **Mignot E** (2005). The hypocretins and narcolepsy: pathophysiology and diagnosis. In: *The Hypocretins: Integrators of Physiological Functions*, (eds) de Lecea L, Sutcliffe JG, Springer: New York, p. 233-252.
57. Fromherz S, **Mignot E**. (2005). Narcolepsy. In: *Current Therapy in Neurological Diseases*, 7th Edition. RT Johnson, JW Griffin, JC cArthur, (eds) Elsevier, p. 18-23.
58. Schenk C, Bassetti C, Arnulf I, **Mignot E** (2007). English Translations of the First Clinical Reports on Narcolepsy by Gélinau and on Cataplexy by Westphal in the Late 19th Century, with Commentary. In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p.7-24.
59. Bassetti C, Billiard M, **Mignot E**, Arnulf I (2007). Klein-Levin Syndrome and Other Recurrent Hypersomnias In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p.89-96.
60. Szklo-Coxe M, Young T, Finn L, **Mignot E** (2007). Automatic behavior, sleep paralysis, hypnagogic hallucinations, cataplexy: Narcolepsy spectrum and alternate etiologies. In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p.133-148.
61. **Mignot E**, Nishino S. Canine narcolepsy: History and pathophysiology (2005). In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p. 231-240.
62. **Mignot E** (2007). CSF hypocretin-1/orexin-A in narcolepsy: Technical aspects and clinical experience. In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p. 287-297.
63. Zeitzer J, **Mignot E** (2007). Role of Hypocretin/Orexin in the Neurobiology of Sleep and Alertness. In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p. 359-374.
64. Lin L, **Mignot E** (2007). Human Leukocyte Antigen and Narcolepsy: Present Status and Relationship with Familial History and Hypocretin Deficiency. In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p.411-426.
65. Faraco J, **Mignot E** (2007). Mutation Screening of the Hypocretin System Genes in Narcolepsy. In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p. 435-442.
66. Nishino S, **Mignot E** (2007). Pharmacology of CNS Stimulants. In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p. .513-530.
67. **Mignot E**, Nishino S (2007). Perspectives for new treatments: a 2005 update. In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p. 641-652.
68. **Mignot E**, Billiard M, Bassetti C (2007). Diagnostic Criteria for Syndromes of Excessive Daytime Sleepiness. In: *Narcolepsy and Hypersomnia*, (eds) Bassetti C, Billiard M, Mignot E, Informa Healthcare, New York, p. 655-661.
69. Nishino S, Mishima K, **Mignot E**, Dement W. Sedative-Hypnotics (2006). In: *Essentials of Clinical Psychopharmacology*, 2nd Edition. Schatzberg A, Nemeroff C, (eds) American Psychiatric Publishing Inc, p. 427-448.
70. **Mignot E** (2006). Narcolepsy. In: *The Dana Guide to Brain Health*, (eds) F Bloom, F Beal, D Kupfer, Free Press, New York, NY, p. 315-318.

71. Chen W, **Mignot E** (2007). Narcolepsy and hypersomnia of central origin: Diagnosis, Differential Pearls, and Management. In: *Review of Sleep Medicine*, 2nd Edition, (eds) Barkoukis TJ and Avidan AY, Butterworth Heinman Elsevier, Philadelphia, p. 75-94.
72. **Mignot E**, Zeitzer J (2006). Neurobiology of narcolepsy and hypersomnia. In: *Neurobiology of Disease*, (eds) Gilman S, Elsevier. p.715-722.
73. Mahakian C, **Mignot E** (2008) A teenage boy with intermittent hypersomnia. In: ICSD2, (eds) AASM, in press.
74. Mahakian C, **Mignot, E** (2008) An adolescent with a major complaint of sleep onset and maintenance insomnia. In: ICSD2, (eds) AASM, in press.
75. Lin L, **Mignot E** (2009). Narcolepsy. In: *Encyclopedia of Neuroscience*, L.R. Squire, ed, Oxford: Academic Press, Vol 6, p 7-14.
76. Nishino S and **Mignot E** (2008). Narcolepsy and Cataplexy. In: *Handbook of Clinical Neurology: Sleep Disorders*, (eds) Montagna P and Chokroverty S, Elsevier, in press.
77. Faracco J and **Mignot E** (2010). Genetics of Sleep and Sleep Disorders. In: *Principles and Practice in Sleep Medicine*, 5th edition, (eds) MH Kyger, T, Roth, WC Dement, WB Sanders Company, Philadelphia, PA, In press.
78. **Mignot E** (2010). Narcolepsy: Pharmacology, Pathophysiology and Genetics. In: *Principles and Practice in Sleep Medicine*, 4th edition, (eds) MH Kyger, T Roth, WC Dement, WB Sanders Company, Philadelphia, PA, in press.
79. **Mignot E** (2010). Narcolepsy: Genetic predisposition and pathophysiology In: *Narcolepsy*, (eds) Goswami M, Pandi-Perumal P, Thorpy M, Springer Verlag, New York in press.
80. **Mignot E** (2010). Etiologies of narcolepsy. In: *Narcolepsy*, (eds) Basetti C, Baumann C, Scammel T, Springer Verlag, New York in press.
81. Roth T, Dauvilliers Y, **Mignot E**, Montplaisir J, Paul J, Swick T, Zee P (2013). Disrupted nighttime sleep in narcolepsy. *J Clin Sleep Med*. 2013 Sep;9(9):955-65.
82. Nishino, S, **Mignot E** (2017). Narcolepsy: Wake-Promoting Medications: Basic Mechanism and Pharmacology. In: *Principles and Practice in Sleep Medicine*, 6th edition, (eds) MH Kyger, T Roth, WC Dement, Elsevier, 2017, Pages 446-461.e5.
83. **Mignot E** (2017). Narcolepsy: Genetics, Immunology, and Pathophysiology. In: *Principles and Practice in Sleep Medicine*, 6th edition, (eds) MH Kyger, T Roth, WC Dement, Elsevier, 2017, Pages 855-872.e7.

Websites:

1. **Mignot E**. Stanford Center for Narcolepsy:
<http://med.stanford.edu/narcolepsy.html>
2. **Mignot E**. Stanford University Center for Sleep Sciences and Medicine:
<http://med.stanford.edu/sleepdivision.html>
3. **Mignot E**. Stanford Health Care - Sleep Medicine Center:
<http://stanfordhospital.org/sleep/>
3. **Mignot E**. HHMI investigator biography and research interests:
http://www.hhmi.org/research/investigators/mignot_bio.html

Books and governmental reports:

1. *Section editor: Mignot E* (2005). Hypersomnia section: all disorders; Normal variant section: short and long sleeper, In: *The International Classification of Sleep Disorders, Diagnostic and Coding Manual (ICSD-2), 2nd edition*, American Academy of Sleep Medicine, Chicago, IL, p.79-115 and p.197-203.
2. *Editor and Author: Bassetti C, Billiard M, Mignot E.* (2007) *Narcolepsy and Hypersomnia*, Informa Healthcare, New York, NY. p. 7-14, p. 89-95, p.133-148, p.231-240, p.287-297, p.359-371, p.411-424, p.435-441, p.513-529, p.641-652, p.655-660, p. 663-670, p. 671-676.
3. *Section editor: Mignot E* (2005). Sleep section, *Neurobiology of Disease*, (eds) Gilman S, Elsevier. p.709-735.
4. *Section editor: Mignot E* (2007). Volume I, *Immunobiology of the Human MHC*, Section D: 13th IHWS Disease Component joint report, D3. Statistical approaches for analyses of HLA-associated and other complex diseases, p.782-787 and p.817-830.
5. *Author: White D, Balkin T, Block G, Buysse D, Dinges DF, Gozal D, Henriksen S, Kinney HC, Landis CA, Mignot E, Owens JA, Siegel JM, Sternberg E, Weese-Mayer DE* (2003). *The 2003 National Sleep Disorders Research Plan*, National Institutes of Health Publication No. 02-5209, pp. 138.
6. *Member: Mignot E* (2006), Committee on Sleep Medicine and Research, *Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem*, Institute on Medicine, The National Academies Press, Washington, DC. pp 404.